image_name
stringlengths 68
68
| type
stringclasses 2
values | gt_table
stringlengths 116
12.6k
|
|---|---|---|
212d6b325b34c178128fdcac9ba2738737eb0ce13083a2699dfd536749f95e93.png | complex | <table><tr><td></td><td>Group 1 (Critical DSS)</td><td>Group 2 (Relative DSS)</td><td>Group 3 (Non- DSS)</td><td><i>p</i>-value</td></tr><tr><td>Vertebral Levels</td><td>27</td><td>148</td><td>15</td><td></td></tr><tr><td rowspan="2">Gender</td><td>F: 11</td><td>F: 19</td><td>F: 4</td><td rowspan="2">0.65</td></tr><tr><td>M: 6</td><td>M: 10</td><td>M:10</td></tr><tr><td rowspan="2">Mean Age at Surgery (Years (±SD))</td><td>F: 68.0 (11.0)</td><td>F: 67.1 (10.4)</td><td>F: 64.5 (9.0)</td><td rowspan="2">0.26</td></tr><tr><td>M: 67.0 (10.3)</td><td>M: 62.1 (12.9)</td><td>M: 47.4 (26.8)</td></tr><tr><td rowspan="2">Mean LF thickness (mm (±SD))</td><td>R: 3.8 (1.4)</td><td>R: 3.4 (1.7)</td><td>R: 3.1 (0.6)</td><td>R: 0.45</td></tr><tr><td>L: 4.0 (1.7)</td><td>L: 3.4 (1.6)</td><td>L: 3.3 (1.1)</td><td>L: 0.30</td></tr><tr><td>Mean Spinal Canal Diameter (mm (±SD))</td><td>12.7 (1.3)</td><td>15.4 (1.3)</td><td>17.7 (2.6)</td><td><0.001*</td></tr><tr><td>Mean Disc Height (mm (±SD))</td><td>10.4 (2.3)</td><td>9.9 (2.5)</td><td>9.7 (2.9)</td><td>0.58</td></tr><tr><td>BMI (±SD)</td><td>22.8 (2.3)</td><td>24.3 (3.2)</td><td>26.7 (3.7)</td><td>0.06</td></tr></table> |
985e0088328a150db58b9968d379f629946e3a4993931d5b214e9063b0b2960e.png | simple | <table><tr><td>N level (kg ha<sup>−1</sup>)</td><td>Plant height (cm)</td><td>Productive tiller hill<sup>−1</sup></td><td>LAI</td><td>Days to maturity (d)</td><td>Number of spikelets panicle<sup>−1</sup></td><td>Fertility (%)</td><td>1000-grain weight (g)</td></tr><tr><td>0</td><td>96</td><td>8.6</td><td>4.6</td><td>105</td><td>83</td><td>89.6</td><td>24.6</td></tr><tr><td>100</td><td>100</td><td>9.1</td><td>5.2</td><td>108</td><td>111</td><td>85.3</td><td>27.6</td></tr><tr><td>125</td><td>103</td><td>12.1</td><td>5.4</td><td>110</td><td>121</td><td>88.6</td><td>26.7</td></tr><tr><td>150</td><td>106</td><td>13.4</td><td>5.6</td><td>112</td><td>134</td><td>92.0</td><td>28.1</td></tr><tr><td>175</td><td>106</td><td>14.2</td><td>6.0</td><td>115</td><td>142</td><td>90.0</td><td>28.1</td></tr><tr><td>200</td><td>108</td><td>14.7</td><td>6.1</td><td>120</td><td>145</td><td>91.0</td><td>28.4</td></tr><tr><td>LSD<sub>0.05</sub></td><td>nsa</td><td>1.2</td><td>0.1</td><td>3.2</td><td>8.7</td><td>ns</td><td>1.05</td></tr></table> |
b9bb6a3099a0d3d4ffb8b5e9fe1a9b78fc5648fd1384942f1947c54da477f063.png | simple | <table><tr><td></td><td>Soil EC</td><td>Nematode gall rating</td><td>P uptake</td><td>GY</td><td>RHL</td><td>RHD</td><td>DSW</td></tr><tr><td>Soil EC</td><td>1</td><td></td><td></td><td></td><td></td><td></td><td></td></tr><tr><td>Nematode gall rating</td><td>–0.07</td><td>1</td><td></td><td></td><td></td><td></td><td></td></tr><tr><td>P uptake</td><td>0.37***</td><td>0.03</td><td>1</td><td></td><td></td><td></td><td></td></tr><tr><td>GY</td><td>0.08</td><td>0.04</td><td> –0.22*</td><td>1</td><td></td><td></td><td></td></tr><tr><td>RHL</td><td>–0.14</td><td>–0.09</td><td> –0.33***</td><td>–0.07</td><td>1</td><td></td><td></td></tr><tr><td>RHD</td><td>0.07</td><td>0.08</td><td>–0.02</td><td>–0.04</td><td>0</td><td>1</td><td></td></tr><tr><td>DSW</td><td>–0.41</td><td>–0.1</td><td> –0.33***</td><td>0.16</td><td>–0.04</td><td>–0.02</td><td>1</td></tr></table> |
6f63db06addbddd8370be3d2be51b2052ca4a131ecb2f3e540035a818c4abf2c.png | simple | <table><tr><td>Characteristics</td><td>No. patients (%)</td><td>Median levels (interquartile range)</td><td><i>p</i></td></tr><tr><td>All patients</td><td>221 (100 %)</td><td>2.228 (0.416)</td><td></td></tr><tr><td>Age (years)</td><td></td><td></td><td>0.773<sup>a</sup></td></tr><tr><td>≤ 40</td><td>33 (14.9 %)</td><td>2.160 (0.566)</td><td></td></tr><tr><td> 41–55</td><td>94 (42.5 %)</td><td>2.215 (0.410)</td><td></td></tr><tr><td> 56–70</td><td>70 (31.7 %)</td><td>2.291 (0.456)</td><td></td></tr><tr><td>> 70</td><td>24 (10.9 %)</td><td>2.198 (0.327)</td><td></td></tr><tr><td>Menopausal status</td><td></td><td></td><td>0.497<sup>b</sup></td></tr><tr><td> Premenopausal</td><td>113 (51.1 %)</td><td>2.200 (0.447)</td><td></td></tr><tr><td> Postmenopausal</td><td>108 (48.9 %)</td><td>2.250 (0.379)</td><td></td></tr><tr><td>Tumor size</td><td></td><td></td><td>0.188<sup>a</sup></td></tr><tr><td> pT1 (≤2 cm)</td><td>109 (49.3 %)</td><td>2.239 (0.356)</td><td></td></tr><tr><td> pT2 (2–5 cm)</td><td>105 (47.5 %)</td><td>2.237 (0.505)</td><td></td></tr><tr><td> pT3/pT4 (>5 cm)</td><td>7 (3.2 %)</td><td>1.830 (0.614)</td><td></td></tr><tr><td>Tumor grade<sup>c</sup></td><td></td><td></td><td>0.700<sup>a</sup></td></tr><tr><td> I</td><td>37 (16.7 %)</td><td>2.207 (0.288)</td><td></td></tr><tr><td> II</td><td>77 (34.8 %)</td><td>2.233 (0.366)</td><td></td></tr><tr><td> III</td><td>101 (45.7 %)</td><td>2.264 (0.491)</td><td></td></tr><tr><td>ER status</td><td></td><td></td><td><0.001<sup>b</sup></td></tr><tr><td> Positive</td><td>125 (56.6 %)</td><td>2.168 (0.407)</td><td></td></tr><tr><td> Negative</td><td>96 (43.4 %)</td><td>2.311 (0.452)</td><td></td></tr><tr><td>PgR status</td><td></td><td></td><td>0.003<sup>b</sup></td></tr><tr><td> Positive</td><td>104 (47.1 %)</td><td>2.159 (0.392)</td><td></td></tr><tr><td> Negative</td><td>117 (52.9 %)</td><td>2.302 (0.425)</td><td></td></tr><tr><td>HER2 status</td><td></td><td></td><td>0.121<sup>b</sup></td></tr><tr><td> Positive</td><td>26 (11.8 %)</td><td>2.299 (0.399)</td><td></td></tr><tr><td> Negative</td><td>195 (88.2 %)</td><td>2.215 (0.432)</td><td></td></tr></table> |
9ffce0699f8d86b67b47f0a8d0eb4430fcb419d3106322fe4154c9b765d149c9.png | complex | <table><tr><td>Disease stage</td><td colspan="3">Least-squared mean (SEM) spleen weight (mg)</td></tr><tr><td></td><td>Negative control (naïve + vehicle)</td><td>Positive control (EAE + vehicle)</td><td>Teriflunomide (EAE + treatment)</td></tr><tr><td>Onset</td><td>467.4 (21.5)</td><td>474.1 (18.5)</td><td>n/a</td></tr><tr><td>Acute attack</td><td>464.8 (11.1)</td><td>347.6 (6.1)<sup>‡</sup></td><td>395.0 (9.6)<sup>†</sup></td></tr><tr><td>Remission</td><td>513.6 (17.4)</td><td>417.4 (10.8)<sup>‡</sup></td><td>472.3 (10.6)**</td></tr><tr><td>Relapse</td><td>513.0 (9.2)</td><td>437.5 (9.7)*</td><td>511.2 (23.8)*</td></tr></table> |
f9344027b6e3386f9e609711c3f2d4686cffd934c31a4f97c488a10170b673b1.png | simple | <table><tr><td>Characteristic</td><td>Frequency (%)</td></tr><tr><td>Age in yrs (mean ± SD)</td><td>80.6 ± 9.3</td></tr><tr><td>Race</td><td> </td></tr><tr><td> White</td><td>25 (49)</td></tr><tr><td> Black</td><td>23 (45)</td></tr><tr><td> Hispanic</td><td>3 (6)</td></tr><tr><td>Gender</td><td> </td></tr><tr><td> Female</td><td>42 (82)</td></tr><tr><td> Male</td><td>9 (18)</td></tr><tr><td>Language</td><td> </td></tr><tr><td> English</td><td>34 (67)</td></tr><tr><td> Non-English</td><td>17 (33)</td></tr><tr><td>Insurance</td><td> </td></tr><tr><td> Medicare</td><td>42 (82)</td></tr><tr><td> Medicaid</td><td>2 (4)</td></tr><tr><td> Medicare managed care</td><td>3 (6)</td></tr><tr><td> Medicare advantage (i.e., senior care options)</td><td>3 (6)</td></tr><tr><td> Other</td><td>1 (2)</td></tr><tr><td>Hospital length of stay in days (mean ± SD)</td><td>6.1 ± 3.4</td></tr></table> |
5d932c8858716b023601b00c1fbdc782bdff43450d1e3c4057bd9c639b2e57d2.png | simple | <table><tr><td></td><td>Never-married</td><td>Married</td><td>Widowed</td><td>Divorced/separated</td></tr><tr><td>Men</td><td></td><td></td><td></td><td></td></tr><tr><td>Number of deaths from all causes</td><td>5325</td><td>19995</td><td>3321</td><td>6533</td></tr><tr><td>Number of deaths from all circulatory diseases</td><td>1679</td><td>6031</td><td>1145</td><td>2025</td></tr><tr><td>Person-years of exposure</td><td>277508</td><td>1818415</td><td>99705</td><td>406618</td></tr><tr><td>Women</td><td></td><td></td><td></td><td></td></tr><tr><td>Number of deaths from all causes</td><td>2027</td><td>10515</td><td>7490</td><td>3938</td></tr><tr><td>Number of deaths from all circulatory diseases</td><td>509</td><td>2248</td><td>2262</td><td>829</td></tr><tr><td>Person-years of exposure</td><td>175001</td><td>1670393</td><td>400626</td><td>447650</td></tr></table> |
cdd5122134cf2e9254e4470e36e7e517804b07b4b6450de6cd66c47bf18ec4fc.png | complex | <table><tr><td rowspan="2">Regulome DB score</td><td>(A)</td><td>(B)</td><td>(C)</td></tr><tr><td>No. of GWAS + LD SNPs (191482)</td><td>No. of (A) SNPs under VDR peaks (572)</td><td>No. of (B) SNPs under VDR peaks enriched for trait association (42)</td></tr><tr><td>1a</td><td>21</td><td>1</td><td>0</td></tr><tr><td>1b</td><td>272</td><td>15</td><td>1</td></tr><tr><td>1c</td><td>6</td><td>0</td><td>0</td></tr><tr><td>1d</td><td>148</td><td>3</td><td>0</td></tr><tr><td>1e</td><td>7</td><td>0</td><td>0</td></tr><tr><td>1f</td><td>3182</td><td>43</td><td>5</td></tr><tr><td>2a</td><td>369</td><td>34</td><td>2</td></tr><tr><td>2b</td><td>3182</td><td>109</td><td>7</td></tr><tr><td>2c</td><td>137</td><td>8</td><td>0</td></tr><tr><td>Total</td><td>7324</td><td>213</td><td>15</td></tr></table> |
24dca732f936317e0540ce7adc15ed52f5f2c20e007af72acdd4e31be6dda01c.png | simple | <table><tr><td>Lamb</td><td>Weight (kg)</td><td>Age (days)</td><td>Total lavage (mL/kg)</td><td>CO<sub>tpud</sub> (mL/kg/min) initial–end</td><td>EVLWI<sub>tpud</sub> (mL/kg) initial</td><td>EVLWI<sub>tpud</sub> (mL/kg) end</td><td>EVLWI<sub>tpdd</sub> (mL/kg) initial</td><td>EVLWI<sub>tpdd</sub> (mL/kg) end</td><td>EVLWI<sub>grav</sub> (mL/kg)</td><td>Final PEEP (mmHg)</td><td>Final OI</td></tr><tr><td>1</td><td>8.1</td><td>21</td><td>125</td><td>221–243</td><td>12.8</td><td>17.0</td><td>11.1</td><td>15.8</td><td>15.1</td><td>7</td><td>19.7</td></tr><tr><td>2</td><td>7.4</td><td>21</td><td>303</td><td>254–66</td><td>NA</td><td>NA</td><td>12.3</td><td>NA</td><td>19.4</td><td>18</td><td>21.2</td></tr><tr><td>3</td><td>4.1</td><td>7</td><td>293</td><td>257–215</td><td>28.6</td><td>28.6</td><td>17.2</td><td>38.6</td><td>28.5</td><td>10</td><td>50.3</td></tr><tr><td>4</td><td>7.4</td><td>14</td><td>68</td><td>279–460</td><td>19.6</td><td>NA</td><td>11.5</td><td>NA</td><td>18.8</td><td>10</td><td>25.0</td></tr><tr><td>5</td><td>10.2</td><td>17</td><td>294</td><td>177–246</td><td>5.3</td><td>19.2</td><td>10.2</td><td>29.9</td><td>17.1</td><td>20</td><td>45.6</td></tr><tr><td>6</td><td>9.4</td><td>18</td><td>191</td><td>217–380</td><td>12.6</td><td>18.6</td><td>11.5</td><td>34.1</td><td>20.1</td><td>20</td><td>54.0</td></tr><tr><td>7</td><td>7.1</td><td>14</td><td>135</td><td>133–151</td><td>22.8</td><td>NA</td><td>16.3</td><td>NA</td><td>16.5</td><td>16</td><td>27.7</td></tr><tr><td>8</td><td>8.0</td><td>15</td><td>420</td><td>165–120</td><td>9.0</td><td>15.2</td><td>14.6</td><td>30.4</td><td>21.5</td><td>25</td><td>36.1</td></tr><tr><td>9</td><td>9.9</td><td>16</td><td>242</td><td>144–165</td><td>6.5</td><td>NA</td><td>21.6</td><td>NA</td><td>18.2</td><td>20</td><td>70.4</td></tr><tr><td>10</td><td>11.5</td><td>19</td><td>184</td><td>152–173</td><td>8.0</td><td>NA</td><td>8.8</td><td>49.1</td><td>29.8</td><td>15</td><td>52.2</td></tr><tr><td>11</td><td>12.3</td><td>22</td><td>98</td><td>150–117</td><td>7.0</td><td>33.3</td><td>NA</td><td>NA</td><td>24.3</td><td>15</td><td>56.8</td></tr><tr><td>12</td><td>5.6</td><td>4</td><td>0</td><td>373</td><td>17.5</td><td>17.5</td><td>NA</td><td>NA</td><td>13.3</td><td>5</td><td>–</td></tr><tr><td>13</td><td>6.7</td><td>4</td><td>0</td><td>253</td><td>15.8</td><td>15.8</td><td>NA</td><td>NA</td><td>11.8</td><td>5</td><td>–</td></tr></table> |
a0849a6b7ed12498cb59db01fc47fa9096f0bce16ae25a06fb62ce7118e65bf1.png | complex | <table><tr><td>Characteristics</td><td>Healthy donors (<i>n</i> = 68)</td><td>Patients (<i>n</i> = 109)</td></tr><tr><td>Age—years<sup>a</sup></td><td>32 (28–40)</td><td>37 (23–48)</td></tr><tr><td>Gender male—no. (%)</td><td>32 (47%)</td><td>38 (34.9%)</td></tr><tr><td>Caucasian race—%</td><td>100%</td><td>100%</td></tr><tr><td>Unrelated families</td><td>NA</td><td>76</td></tr><tr><td>Age at onset—years<sup>a</sup></td><td>NA</td><td>6 (3–14)</td></tr><tr><td colspan="3">C1-INH-HAE—no. (%)</td></tr><tr><td> Type I</td><td>NA</td><td>104 (95.4%)</td></tr><tr><td> Type II</td><td>NA</td><td>5 (4.5%)</td></tr><tr><td colspan="3">Prophylaxis—no. (%)</td></tr><tr><td> Tranexamic acid</td><td>NA</td><td>4 (3.8%)</td></tr><tr><td> Attenuated androgens</td><td>NA</td><td>15 (10%)</td></tr><tr><td>≥12 attacks/year—no. (%)</td><td>NA</td><td>40 (36.7%)</td></tr></table> |
1a270476bca73d58d866f80cf128cae7700eecc63271c1af4945278472d3dfc8.png | complex | <table><tr><td rowspan="2">Items</td><td colspan="6">Results of two–way repeated measures ANOVA</td></tr><tr><td>Variables</td><td>SS (Type III)</td><td>DF</td><td>MF</td><td>F</td><td>p-value</td></tr><tr><td rowspan="3">Systolic blood pressure (mmHg)</td><td>Time</td><td>3778.705</td><td>1</td><td>3778.705</td><td>15.089</td><td><0.001</td></tr><tr><td>Time* like or dislike</td><td>0.250</td><td>1</td><td>0.250</td><td>0.001</td><td>0.975</td></tr><tr><td>Like or dislike</td><td>2825.875</td><td>1</td><td>2825.875</td><td>4.338</td><td>0.043</td></tr><tr><td rowspan="3">Diastolic blood pressure (mmHg)</td><td>Time</td><td>87.547</td><td>1</td><td>87.547</td><td>1.811</td><td>0.186</td></tr><tr><td>Time* like or dislike</td><td>8.002</td><td>1</td><td>8.002</td><td>0.166</td><td>0.686</td></tr><tr><td>Like or dislike</td><td>292.517</td><td>1</td><td>292.517</td><td>0.702</td><td>0.407</td></tr><tr><td rowspan="2">Pulse rate (bpm)</td><td>Time</td><td>172.163</td><td>1</td><td>172.163</td><td>11.987</td><td>0.001</td></tr><tr><td>Time* like or dislike</td><td>12.891</td><td>1</td><td>12.891</td><td>0.898</td><td>0.349</td></tr><tr><td> </td><td>Like or dislike</td><td>843.857</td><td>1</td><td>843.857</td><td>6.159</td><td>0.017</td></tr></table> |
bbad9d98ac18ca1192416e5263f9f58e348729b398d2bc3c88602b534a67b76d.png | complex | <table><tr><td rowspan="2"></td><td colspan="4">RR interval expressions involved in QTc calculations</td><td colspan="3">Intra-subject comparison with individual QT/RR hysteresis</td></tr><tr><td>Individual hysteresis</td><td>Universal hysteresis</td><td>10 s RR average</td><td>3-interval RR average</td><td>Universal hysteresis</td><td>10 s RR average</td><td>3-interval RR average</td></tr><tr><td>QTc SD [ms]</td><td>5.49 ± 1.10</td><td>5.52 ± 1.11</td><td>10.49 ± 1.94</td><td>11.41 ± 2.11</td><td>0.03 ± 0.11</td><td>5.00 ± 1.51</td><td>5.92 ± 1.68</td></tr><tr><td>QTc<sub>L</sub> SD [ms]</td><td>5.67 ± 1.14</td><td>5.70 ± 1.15</td><td>10.68 ± 2.00</td><td>11.58 ± 2.17</td><td>0.02 ± 0.08</td><td>5.00 ± 1.52</td><td>5.91 ± 1.68</td></tr><tr><td>QTc<sub>P</sub> SD [ms]</td><td>6.01 ± 1.21</td><td>6.04 ± 1.22</td><td>11.37 ± 2.07</td><td>12.31 ± 2.25</td><td>0.02 ± 0.01</td><td>5.37 ± 1.65</td><td>6.30 ± 1.81</td></tr><tr><td>QTcF SD [ms]</td><td>6.68 ± 1.71</td><td>6.72 ± 1.72</td><td>12.80 ± 2.09</td><td>14.08 ± 2.28</td><td>0.04 ± 0.09</td><td>6.08 ± 2.06</td><td>7.36 ± 2.25</td></tr></table> |
805910aab729203a9bea225d0c0c59d1edd265af509f47a2981359c5131bdf76.png | simple | <table><tr><td>Facit-fatigue score</td><td>Mean (SE)*</td><td><i>P</i> change from pre-SBRT<sup>#</sup></td></tr><tr><td>Pre-SBRT</td><td>43.78 (1.43)</td><td>−</td></tr><tr><td>Post-SBRT (Month)</td></tr><tr><td> 1</td><td>40.66 (1.43)</td><td>0.02</td></tr><tr><td> 3</td><td>42.81 (1.43)</td><td>0.37</td></tr><tr><td> 6</td><td>43.07 (1.45)</td><td>0.87</td></tr><tr><td> 9</td><td>41.13 (1.45)</td><td>0.40</td></tr><tr><td> 12</td><td>43.18 (1.43)</td><td>0.61</td></tr></table> |
96fc6b9bf6d1dce2aeffc7ab43650cfa8704a8f3335587c1632210ea4356e0b9.png | complex | <table><tr><td colspan="2">Characteristics</td><td>Adjusted OR (95% CI)</td><td><i>p</i>-Value</td></tr><tr><td colspan="4">Age percentile (years)</td></tr><tr><td rowspan="5"></td><td>1–20 (18–46.9) </td><td>Reference</td><td></td></tr><tr><td>21–40 (47–59.9) </td><td>0.51 (0.18–1.39)</td><td>0.19</td></tr><tr><td>41–60 (60–66.9)</td><td>0.58 (0.20–1.64)</td><td>0.30</td></tr><tr><td>61–80 (67–74.9)</td><td>0.30 (0.09–1.00)</td><td>0.05</td></tr><tr><td>80–100 (75+)</td><td>0.33 (0.10–1.10)</td><td>0.73</td></tr><tr><td colspan="4">Highest level of education attained </td></tr><tr><td rowspan="4"></td><td>High school equivalent of year 10 or lower</td><td>Reference</td><td></td></tr><tr><td>High school completion</td><td>1.15 (0.35–3.80)</td><td>0.82</td></tr><tr><td>Diploma or trade certificate</td><td>1.77 (0.74–4.25)</td><td>0.20</td></tr><tr><td>Bachelor’s or postgraduate degree</td><td>2.57 (0.99–6.67)</td><td>0.05</td></tr><tr><td colspan="4">Reason for attending <sup>1</sup></td></tr><tr><td rowspan="4"></td><td>To discuss symptoms, treatments or tests for diagnosed condition</td><td>Reference</td><td></td></tr><tr><td>To discuss symptoms or tests for undiagnosed condition</td><td>0.62 (0.06–6.47)</td><td>0.69</td></tr><tr><td>To receive tests or treatments for diagnosed condition</td><td>4.83 (1.29–18.04)</td><td>0.02</td></tr><tr><td>For a routine exam for a diagnosed condition</td><td>1.92 (0.52–7.05)</td><td>0.33</td></tr><tr><td colspan="2">Appointment frequency in the last 6 months (continuous)</td><td>1.41 (1.00–1.99)</td><td>0.05</td></tr><tr><td colspan="4">Health insurance coverage</td></tr><tr><td rowspan="2"></td><td>Private health insurance</td><td>Reference</td><td></td></tr><tr><td>No private health insurance coverage</td><td>2.10 (0.96–4.60)</td><td>0.06</td></tr></table> |
3596bcbcbe24ddbfbe9bcc054b2436ee2ea424c2934104ab2373a4bccac960a5.png | complex | <table><tr><td rowspan="2">Author, year</td><td rowspan="2">Age at diagnosis</td><td colspan="5">Presentation</td><td rowspan="2">TSH receptor antibody</td><td rowspan="2">Cervical thyroidectomy before diagnosis struma ovarii</td><td rowspan="2">Prior pelvic exam that result negative</td><td rowspan="2">Ovarian scan before abdominal surgery</td><td colspan="3">Ovarian findings</td><td rowspan="2">Years after Graves’ disease diagnosis</td></tr><tr><td>Exoph-thalmos</td><td>Thyroid bruit</td><td>Pelvic pressure symptoms</td><td>Pleural effusion</td><td>Ascites</td><td>Side</td><td>Maximum diameter (cm)</td><td>Malignancy</td></tr><tr><td>Kampers, 1970 [7]</td><td>64</td><td>Yes</td><td>NA</td><td>NA</td><td>NA</td><td>NA</td><td>NA</td><td>Yes</td><td>NA</td><td>NA</td><td>NA</td><td>NA</td><td>No</td><td>18</td></tr><tr><td>Lefort, 1981 [9]</td><td>38</td><td>Yes</td><td>NA</td><td>NA</td><td>No</td><td>No</td><td>Positive</td><td>NA</td><td>NA</td><td>Positive</td><td>Right</td><td>7</td><td>No</td><td>12</td></tr><tr><td>Lazarus, 1987 [15]</td><td>48</td><td>Yes</td><td>NA</td><td>NA</td><td>NA</td><td>Few</td><td>Positive</td><td>Yes</td><td>14 years</td><td>Positive</td><td>Left</td><td>9</td><td>No</td><td>24</td></tr><tr><td>Kung, 1990 [10]</td><td>40</td><td>No</td><td>NA</td><td>No</td><td>NA</td><td>No</td><td>Positive</td><td>No</td><td>23 weeks</td><td>NA</td><td>Right</td><td>5</td><td>No</td><td>4</td></tr><tr><td>Banyot, 1995 [1]</td><td>30</td><td>No</td><td>No</td><td>Yes</td><td>NA</td><td>NA</td><td>Negative</td><td>No</td><td>NA</td><td>Positive</td><td>Right</td><td>7</td><td>NA</td><td>0</td></tr><tr><td>Grandet, 2000 [16]</td><td>78</td><td>NA</td><td>NA</td><td>NA</td><td>NA</td><td>Few</td><td>NA</td><td>Yes</td><td>NA</td><td>Positive</td><td>Bilateral</td><td>10</td><td>No</td><td>4</td></tr><tr><td>Kano, 2000 [8]</td><td>50</td><td>NA</td><td>NA</td><td>NA</td><td>NA</td><td>Yes</td><td>Positive</td><td>No</td><td>NA</td><td>NA</td><td>Left</td><td>7</td><td>Yes</td><td>0</td></tr><tr><td>Mimura, 2001 [6]</td><td>26</td><td>No</td><td>No</td><td>NA</td><td>NA</td><td>NA</td><td>Positive</td><td>No</td><td>NA</td><td>Positive</td><td>Left</td><td>16</td><td>No</td><td>4</td></tr><tr><td>Sussman, 2002 [17]</td><td>53</td><td>No</td><td>NA</td><td>No</td><td>NA</td><td>NA</td><td>NA</td><td>No</td><td>NA</td><td>NA</td><td>Right</td><td>7.5</td><td>Yes</td><td>5</td></tr><tr><td>Bartel, 2005 [18]</td><td>54</td><td>NA</td><td>NA</td><td>NA</td><td>NA</td><td>NA</td><td>Positive</td><td>Yes</td><td>NA</td><td>Positive</td><td>Left</td><td>NA</td><td>No</td><td>23</td></tr><tr><td>Guida, 2005 [11]</td><td>42</td><td>Yes</td><td>NA</td><td>NA</td><td>No</td><td>Marked</td><td>NA</td><td>Yes</td><td>NA</td><td>Negative</td><td>Right</td><td>12</td><td>No</td><td>1</td></tr><tr><td>Teale, 2006 [4]</td><td>36</td><td>Yes</td><td>NA</td><td>NA</td><td>NA</td><td>NA</td><td>Positive</td><td>Yes</td><td>NA</td><td>NA</td><td>Left</td><td>13.5</td><td>No</td><td>8</td></tr><tr><td>Chiofalo, 2007 [19]</td><td>42</td><td>No</td><td>NA</td><td>Yes</td><td>NA</td><td>Yes</td><td>Positive</td><td>Yes</td><td>NA</td><td>Positive</td><td>Right</td><td>12</td><td>No</td><td>0.5</td></tr><tr><td>Wong, 2009 [2]</td><td>44</td><td>Yes</td><td>Yes</td><td>Yes</td><td>NA</td><td>NA</td><td>Positive</td><td>Yes</td><td>NA</td><td>NA</td><td>Left</td><td>NA</td><td>Yes</td><td>1</td></tr><tr><td>Anastasilakis, 2013 [3]</td><td>49</td><td>No</td><td>NA</td><td>NA</td><td>Yes</td><td>Moderate</td><td>Positive</td><td>No</td><td>NA</td><td>NA</td><td>Right</td><td>18</td><td>No</td><td>2</td></tr><tr><td>Our case, 2015</td><td>56</td><td>Yes</td><td>No</td><td>No</td><td>No</td><td>Minimal</td><td>Positive</td><td>Yes</td><td>Not done</td><td>Positive</td><td>Right</td><td>8</td><td>No</td><td>23</td></tr></table> |
c39ab9990cec49d6ecf88c2fb5f2c4f00c9a0745788892d2b55de7d51f1e3d05.png | complex | <table><tr><td colspan="4">Pif + VMY <i>vs</i>. VMY</td></tr><tr><td>Up-regulated</td><td>Fold</td><td>Down-regulated</td><td>Fold</td></tr><tr><td>EndoG</td><td>8.77809E+30</td><td>FIGF</td><td>−6.10476E+11</td></tr><tr><td>CIDEB</td><td>1.9687E+12</td><td>ANGPT4</td><td>−6.017072518</td></tr><tr><td>PRSS54</td><td>1299.03</td><td>GSK3A</td><td>−5.35</td></tr><tr><td>BIK</td><td>19.44</td><td>INCA1</td><td>−5.18</td></tr><tr><td>MAP3K9</td><td>18.19</td><td>TNFSF14</td><td>−4.01</td></tr><tr><td>ERBB3</td><td>15.17</td><td>GDF15</td><td>−4.01</td></tr><tr><td>BRAT1</td><td>7.48</td><td>HGF</td><td>−3.89</td></tr><tr><td>CISH</td><td>6.73</td><td>BIRC3</td><td>−3.41</td></tr><tr><td>FADD</td><td>6.73</td><td>LIF</td><td>−2.85</td></tr><tr><td>TP63</td><td>6.63</td><td>NTF3</td><td>−2.77</td></tr><tr><td>CBX6</td><td>6.23</td><td>DRD2</td><td>−2.75</td></tr><tr><td>SRC</td><td>5.98</td><td>SNCG</td><td>−2.67</td></tr><tr><td>CBX7</td><td>5.98</td><td>MAGEA9</td><td>−2.67</td></tr><tr><td>HDAC4</td><td>5.24</td><td>ZNF385D</td><td>−2.67</td></tr><tr><td>RASSF4</td><td>4.49</td><td>CRIP3</td><td>−2.67</td></tr><tr><td>TRPM8</td><td>4.49</td><td>TNFSF15</td><td>−2.45</td></tr><tr><td>ERBB2</td><td>4.06</td><td>NAP1L6</td><td>−2.45</td></tr><tr><td>AKT1</td><td>3.84</td><td>TENC1</td><td>−2.33</td></tr><tr><td>UNC5B</td><td>3.83</td><td>NRCAM</td><td>−2.23</td></tr><tr><td>TNFRSF10D</td><td>3.74</td><td>DNAJB7</td><td>−2.21</td></tr><tr><td>NLRP12-14</td><td>3.74</td><td>MAGEB2</td><td>−2.19</td></tr><tr><td>TP73</td><td>3.74</td><td>PPAPDC2</td><td>−2.14</td></tr><tr><td>ARHGEF18</td><td>3.55</td><td>PRSS12</td><td>−2.14</td></tr><tr><td>TNFRSF25</td><td>3.49</td><td>CFLAR</td><td>−2.07</td></tr><tr><td>FASTK</td><td>3.48</td><td>GADD45A</td><td>−2.07</td></tr></table> |
50d31aaa2d9a3ecc5f3e64d16c47188e442256e2610ca399b4dbbd210682d3eb.png | simple | <table><tr><td></td><td>Antenatal Survey (<i>n</i>=180)</td><td>Postnatal Survey (<i>n</i>=228)</td></tr><tr><td>Median age at participation (IQR)</td><td>27.4 years (24.8, 30.9)</td><td>28.3 years (24.8, 31.9)</td></tr><tr><td>Marital status</td><td></td><td></td></tr><tr><td> Married</td><td>96/180 (53 %)</td><td>99/228 (43 %)</td></tr><tr><td> Cohabiting</td><td>50/180 (28 %)</td><td>84/228 (37 %)</td></tr><tr><td> Single</td><td>34/180 (19 %)</td><td>45/228 (20 %)</td></tr><tr><td>Living as only adult in household</td><td>12/179 (7 %)</td><td>28/225 (12 %)</td></tr><tr><td>Disclosure of HIV status</td><td></td><td></td></tr><tr><td> To husband/partner or family or friend(s)</td><td>162/178 (91 %)</td><td>210/222 (95 %)</td></tr><tr><td> To no one at all</td><td>16/178 (9 %)</td><td>12/222 (5 %)</td></tr><tr><td>Smoking, alcohol and drug use<sup>a</sup></td><td></td><td></td></tr><tr><td> Current smoker</td><td>47/178 (26 %)</td><td>74/225 (33 %)</td></tr><tr><td> Current alcohol use</td><td>15/179 (8 %)</td><td>18/224 (8 %)</td></tr><tr><td> Ever used marijuana</td><td>25/178 (14 %)</td><td>27/228 (12 %)</td></tr><tr><td> Ever used illicit drugs other than marijuana</td><td>23/174 (13 %)</td><td>23/215 (11 %)</td></tr><tr><td>Use of support services<sup>a</sup></td><td></td><td></td></tr><tr><td> Currently using support group</td><td>10/180 (5 %)</td><td>33/228 (14 %)</td></tr><tr><td> Currently using peer counselling</td><td>9/180 (5 %)</td><td>85/228 (37 %)</td></tr><tr><td> Currently using social services</td><td>39/180 (22 %)</td><td>82/228 (36 %)</td></tr><tr><td> Currently using adherence programme</td><td>4/180 (2 %)</td><td>43/228 (19 %)</td></tr><tr><td>On ART for 4 weeks preceding survey<sup>b</sup></td><td>180/180 (100 %)</td><td>101/228 (44 %)</td></tr></table> |
0ff4c9673670280d46ca25fbd42bc82d83f78fbd69ef8dde42f24ea45efa46a3.png | complex | <table><tr><td rowspan="2">Thin Film</td><td colspan="2">C<sub>3</sub>H<sub>8</sub> (1 ppm)</td></tr><tr><td>T<sub>recovery</sub> (s)</td><td>T<sub>response</sub> (s)</td></tr><tr><td>CuO</td><td>20</td><td>12</td></tr><tr><td>Au:CuO</td><td>30</td><td>34</td></tr><tr><td>Ag:CuO</td><td>26</td><td>18</td></tr><tr><td>Cr:CuO</td><td>10</td><td>24</td></tr><tr><td>Pd:CuO</td><td>35</td><td>15</td></tr><tr><td>Pt:CuO</td><td>55</td><td>12</td></tr><tr><td>Sb:CuO</td><td>92</td><td>30</td></tr><tr><td>Si:CuO</td><td>150</td><td>100</td></tr></table> |
ba38fdf498a57824e7756faa1903b12f25f2c951ae853572bd8891738db48345.png | simple | <table><tr><td><i>Characteristic</i></td><td><i>Impaired</i><sup>†</sup><i>and Inadequate Reading Ability (S-TOFHLA < 16)</i><sup>‡</sup></td><td><i>Impaired</i><sup>†</sup><i>and Limited Reading Ability (S-TOFHLA < 23)</i><sup>‡</sup></td></tr><tr><td>Sensitivity (%)</td><td>67 (58, 76)</td><td>54 (47, 61)</td></tr><tr><td>Specificity (%)</td><td>82 (80, 85)</td><td>83 (81, 86)</td></tr><tr><td>Positive Predictive Power</td><td>0.31 (0.25, 0.37)</td><td>0.40 (0.34, 0.47)</td></tr><tr><td>Negative Predictive Power</td><td>0.96 (0.94, 0.97)</td><td>0.90 (0.88, 0.92)</td></tr><tr><td>Likelihood Ratio Positive (LR +)</td><td>3.79 (3.12, 4.6)</td><td>3.28 (2.67, 4.03)</td></tr><tr><td>Likelihood Ratio Negative (LR -)</td><td>0.40 (0.30, 0.53)</td><td>0.55 (0.47, 0.65)</td></tr><tr><td>Area under the ROC curve</td><td>0.78 (0.73,0.83)</td><td>0.73 (0.69, 0.78)</td></tr></table> |
8f6310f73a45fd785132f25a1e789899942dcb392884555cbb0f631a04ca4cc6.png | complex | <table><tr><td rowspan="2">Subscales</td><td>Pretest</td><td>Posttest</td></tr><tr><td>Mean (SD)</td><td>Mean (SD)</td></tr><tr><td>Physical</td><td>55.5 (35.8)</td><td>53.5 (38.1)</td></tr><tr><td>Role</td><td>57.8 (32.4)</td><td>59.8 (28.6)</td></tr><tr><td>Bodily pain</td><td>59.0 (33.8)</td><td>61.0 (37.5)</td></tr><tr><td>General health</td><td>49.0 (24.6)</td><td>49.8 (26.2)</td></tr><tr><td>Vitality</td><td>48.5 (28.3)</td><td>46.5 (28.6)</td></tr><tr><td>Social</td><td>72.0 (28.4)</td><td>71.5 (29.9)</td></tr><tr><td>Role/emotional</td><td>62.3 (31.4)</td><td>73.8 (28.2)</td></tr><tr><td>Mental health</td><td>53.3 (13.1)</td><td>63.3 (19.6)</td></tr><tr><td>PCS</td><td>55.3 (24.0)</td><td>55.3 (26.3)</td></tr><tr><td>MCS</td><td>59.8 (19.1)</td><td>63.8 (20.3)*</td></tr></table> |
2e8355ef7ad9437f216b772522d1ca6503eb678230bf8589e5453a9a2d8dad36.png | simple | <table><tr><td>Characteristics</td><td>Median kappa coefficient (range)</td></tr><tr><td>Characteristics day 1</td><td></td></tr><tr><td>Position of the pronuclei</td><td>0.74 (0.65-0.77)</td></tr><tr><td>Size of the pronuclei</td><td>0.44 (0.33-0.57)</td></tr><tr><td>Cytoplasmic halo</td><td>-0.34 (-0.62-0)</td></tr><tr><td>Characteristics day 2</td><td></td></tr><tr><td>Number of blastomeres</td><td>0.82 (0.80-0.93)</td></tr><tr><td>Degree of fragmentation</td><td>0.58 (0.53-0.62)</td></tr><tr><td>Size of blastomeres</td><td>0.59 (0.48-0.62)</td></tr><tr><td>Characteristics day 3</td><td></td></tr><tr><td>Number of blastomeres</td><td>0.67 (0.57-0.82)</td></tr><tr><td>Degree of fragmentation</td><td>0.59 (0.51-0.65)</td></tr><tr><td>Size of blastomeres</td><td>0.55 (0.47-0.76)</td></tr><tr><td>Decision</td><td>0.75 (0.72-0.88)</td></tr></table> |
dd25ebd53846d3df96921e17709adb16ee841c7d93d78b37cea74c06d280063b.png | simple | <table><tr><td>Sample</td><td>D<sub>10</sub> (μm)</td><td>D<sub>50</sub> (μm)</td><td>D<sub>90</sub> (μm)</td><td>CI (%)</td></tr><tr><td>Untreated</td><td>8.39 ± 0.24 <sup>a</sup></td><td>23.43 ± 0.32 <sup>a</sup></td><td>54.50 ± 0.61 <sup>a</sup></td><td>56.29 ± 0.08 <sup>a</sup></td></tr><tr><td>MCC1.0 h</td><td>5.35 ± 0.02 <sup>b</sup></td><td>15.90 ± 0.10 <sup>b</sup></td><td>40.43 ± 0.78 <sup>c</sup></td><td>47.89 ± 0.06 <sup>b</sup></td></tr><tr><td>MCC2.0 h</td><td>4.36 ± 0.06 <sup>c</sup></td><td>13.63 ± 0.21 <sup>c</sup></td><td>40.40 ± 1.51 <sup>c</sup></td><td>41.12 ± 0.09 <sup>c</sup></td></tr><tr><td>MCC3.0 h</td><td>4.18 ± 0.01 <sup>d</sup></td><td>13.20 ± 0.17 <sup>d</sup></td><td>48.73 ± 6.55 <sup>b</sup></td><td>36.44 ± 0.09 <sup>d</sup></td></tr><tr><td>MCC4.0 h</td><td>4.24 ± 0.04 <sup>c,d</sup></td><td>13.20 ± 0.17 <sup>d</sup></td><td>40.80 ± 3.70 <sup>c</sup></td><td>34.81 ± 0.08 <sup>e</sup></td></tr><tr><td>MCC6.0 h</td><td>3.76 ± 0.08 <sup>e</sup></td><td>11.50 ± 0.20 <sup>e</sup></td><td>29.97 ± 0.72 <sup>d</sup></td><td>31.63 ± 0.01 <sup>f</sup></td></tr><tr><td>MCC8.0 h</td><td>3.51 ± 0.07 <sup>f</sup></td><td>10.53 ± 0.06 <sup>f</sup></td><td>27.77 ± 0.47 <sup>d,e</sup></td><td>29.75 ± 0.03 <sup>g</sup></td></tr><tr><td>MCC12.0 h</td><td>3.21 ± 0.03 <sup>g</sup></td><td>9.72 ± 0.03 <sup>g</sup></td><td>24.70 ± 0.35 <sup>e</sup></td><td>25.24 ± 0.07 <sup>h</sup></td></tr><tr><td>MCC16.0 h</td><td>3.17 ± 0.09 <sup>g</sup></td><td>9.43 ± 0.12 <sup>g</sup></td><td>24.17 ± 0.40 <sup>e</sup></td><td>25.17 ± 0.02 <sup>h</sup></td></tr></table> |
0c874d20efa4c5e871f1aa7b428c1391c0b5ca06448c2c23af4940bb9c19fdd9.png | simple | <table><tr><td>Gene</td><td>Tissue</td><td><i>n</i></td><td>Effect size (se)</td><td><i>p</i> value</td></tr><tr><td><i>MRPS6</i></td><td>Aortic artery</td><td>197</td><td>0.15 (0.05)</td><td>3.5 × 10<sup>−3</sup></td></tr><tr><td><i>MRPS6</i></td><td>Coronary artery</td><td>118</td><td>0.14 (0.11)</td><td>0.22</td></tr><tr><td><i>MRPS6</i></td><td>Tibial artery</td><td>285</td><td>0.15 (0.05)</td><td>1.8 × 10<sup>−3</sup></td></tr><tr><td><i>MRPS6</i></td><td>Atrial appendage</td><td>159</td><td>−0.02 (0.09)</td><td>0.88</td></tr><tr><td><i>MRPS6</i></td><td>Left ventricle (heart)</td><td>190</td><td>−0.16 (0.10)</td><td>0.09</td></tr><tr><td><i>MRPS6</i></td><td>Liver</td><td>97</td><td>−0.19 (0.14)</td><td>0.17</td></tr><tr><td><i>MRPS6</i></td><td>Whole blood</td><td>338</td><td>−0.09 (0.04)</td><td>0.04</td></tr><tr><td><i>KCNE2</i></td><td>Aortic artery</td><td>197</td><td>0.13 (0.07)</td><td>0.06</td></tr><tr><td><i>KCNE2</i></td><td>Coronary artery</td><td>118</td><td>0.09 (0.11)</td><td>0.43</td></tr><tr><td><i>KCNE2</i></td><td>Tibial artery</td><td>285</td><td>0.15 (0.06)</td><td>0.02</td></tr><tr><td><i>KCNE2</i></td><td>Atrial appendage</td><td>159</td><td>0.13 (0.16)</td><td>0.41</td></tr><tr><td><i>KCNE2</i></td><td>Left ventricle (heart)</td><td>190</td><td>−0.06 (0.14)</td><td>0.71</td></tr><tr><td><i>KCNE2</i></td><td>Liver</td><td>97</td><td>0.05 (0.15)</td><td>0.31</td></tr><tr><td><i>KCNE2</i></td><td>Whole blood</td><td>338</td><td>8.40 × 10<sup>−3</sup> (0.15)</td><td>0.92</td></tr></table> |
6fbf65fce39f8cdb70e8047057b0cb7eb9f772187ccbb6938883545090bded66.png | complex | <table><tr><td>Name of the test</td><td>Procedure</td><td>Results</td></tr><tr><td rowspan="2">Alkaloids</td><td>Mayer's test</td><td>+</td></tr><tr><td>Hager's test</td><td>+</td></tr><tr><td>Saponins</td><td>Froth test</td><td>−</td></tr><tr><td rowspan="2">Flavonoids</td><td>Shinoda's test</td><td>+</td></tr><tr><td>Lead acetate test</td><td>+</td></tr><tr><td>Tannins</td><td>Gelatin test</td><td>+</td></tr><tr><td rowspan="2">Glycosides</td><td>Libermann's Test</td><td>−</td></tr><tr><td>Keller Killiant's Test</td><td>−</td></tr><tr><td>Polyphenols</td><td>Test for polyphenol</td><td>+</td></tr><tr><td>Total alkaloid content (mg of RE/g dry weight of CRE)</td><td> </td><td>0.0000703</td></tr><tr><td>Total flavonoid content (mg of QE/g dry weight of CRE)</td><td> </td><td>0.077825</td></tr><tr><td>Total polyphenol content (mg of GAE/g dry weight of CRE)</td><td> </td><td>0.110772</td></tr></table> |
efc79fb6a556cbadf9416c59c2e649d5e7e492b6fa564ad2abf02096a527b1ff.png | simple | <table><tr><td>Environmental Samples</td><td>16S rRNA Positives (%)</td></tr><tr><td>Plant biofilms</td><td>12/18 (66.7 <sup>a</sup>)</td></tr><tr><td>Water filtrates</td><td>12/12 (100 <sup>a</sup>)</td></tr><tr><td>Plant detritus</td><td>8/15 (53.3 <sup>a</sup>)</td></tr><tr><td>Soils</td><td>8/15 (53.3 <sup>a</sup>)</td></tr></table> |
80bd802e97b26519715306f8f20491ec31374dd1297bf6cfde08fcd3d970b655.png | simple | <table><tr><td>Classification</td><td>Name of model</td></tr><tr><td>Peripheral NP</td><td>Neuroma model</td></tr><tr><td></td><td>Chronic constriction injury model (CCI)</td></tr><tr><td></td><td>Partial sciatic nerve ligation model (PSL or Seltzer</td></tr><tr><td></td><td>model)</td></tr><tr><td></td><td>L5/L6 spinal nerve ligation model (SNL)</td></tr><tr><td></td><td>Spared nerve injury</td></tr><tr><td></td><td>Sciatic cryoneurolysis model (SCN)</td></tr><tr><td></td><td>Inferior caudal trunk resection model (ICTR)</td></tr><tr><td></td><td>Sciatic inflammatory neuritis model (SIN)</td></tr><tr><td></td><td>Postherpetic neuralgia model (PHN)</td></tr><tr><td></td><td>Diabetic neuropathic pain model</td></tr><tr><td></td><td>Drugs-induced peripheral neuropathy model</td></tr><tr><td></td><td>Bone cancer pain models</td></tr><tr><td></td><td>HIV-induced neuropathy model</td></tr><tr><td></td><td>Trigeminal Neuralgia model</td></tr><tr><td></td><td>Orofacial pain model</td></tr><tr><td>Central NP</td><td>Excitotoxic spinal cord injury (ESCI)</td></tr><tr><td></td><td>Photochemical SCI model</td></tr><tr><td></td><td>Weight-drop or contusive SCI (Allen's Model)</td></tr><tr><td></td><td>Spinal hemisection</td></tr></table> |
fc0d93087331ac40b299a5125d22841add004b0e437801281235ae468d2f0073.png | complex | <table><tr><td rowspan="2">SNP ID</td><td rowspan="2">Model</td><td rowspan="2">Genotype</td><td colspan="3">Gastric cancer</td><td colspan="3">Colorectal cancer</td></tr><tr><td colspan="2">OR (95 % CI)</td><td><i>P</i> value</td><td colspan="2">OR (95 % CI)</td><td><i>P</i> value</td></tr><tr><td>rs10795668</td><td>Allele model</td><td>A/G</td><td>0.94</td><td>(0.80–1.10)</td><td>0.419</td><td>0.86</td><td>(0.70–1.02)</td><td>0.082</td></tr><tr><td></td><td>Overdominant model</td><td>A/G</td><td>0.97</td><td>(0.76–1.23)</td><td>0.78</td><td>0.89</td><td>(0.68–1.17)</td><td>0.41</td></tr><tr><td></td><td>Log - additive model</td><td>–</td><td>0.95</td><td>(0.80–1.13)</td><td>0.56</td><td>0.86</td><td>(0.71–1.04)</td><td>0.12</td></tr><tr><td>rs10788473</td><td>Allele model</td><td>T/C</td><td>1.04</td><td>(0.88–1.22)</td><td>0.655</td><td>0.98</td><td>(0.82–1.17)</td><td>0.817</td></tr><tr><td></td><td>Overdominant model</td><td>T/C</td><td>0.86</td><td>(0.68–1.10)</td><td>0.24</td><td>1.06</td><td>(0.81–1.39)</td><td>0.66</td></tr><tr><td></td><td>Log - additive model</td><td>–</td><td>1.04</td><td>(0.88–1.24)</td><td>0.63</td><td>0.91</td><td>(0.75–1.11)</td><td>0.34</td></tr><tr><td>rs1665650</td><td>Allele model</td><td>A/G</td><td>1.02</td><td>(0.86–1.21)</td><td>0.85</td><td>1.09</td><td>(0.91–1.30)</td><td>0.363</td></tr><tr><td></td><td>Overdominant model</td><td>A/G</td><td>0.77</td><td>(0.60–0.99)</td><td>0.038*</td><td>1.04</td><td>(0.80–1.36)</td><td>0.78</td></tr><tr><td></td><td>Log - additive model</td><td>–</td><td>1</td><td>(0.83–1.20)</td><td>0.99</td><td>1.16</td><td>(0.95–1.42)</td><td>0.15</td></tr><tr><td>rs12413624</td><td>Allele model</td><td>A/T</td><td>0.9</td><td>(0.77–1.05)</td><td>0.191</td><td>0.81</td><td>(0.68–0.96)</td><td>0.018*</td></tr><tr><td></td><td>Overdominant model</td><td>A/T</td><td>0.91</td><td>(0.72–1.17)</td><td>0.47</td><td>0.9</td><td>(0.69–1.18)</td><td>0.44</td></tr><tr><td></td><td>Log - additive model</td><td>–</td><td>0.93</td><td>(0.77–1.11)</td><td>0.39</td><td>0.81</td><td>(0.66–0.98)</td><td>0.032*</td></tr><tr><td>rs10500715</td><td>Allele model</td><td>G/T</td><td>1.09</td><td>(0.90–1.32)</td><td>0.387</td><td>1.04</td><td>(0.85–1.28)</td><td>0.699</td></tr><tr><td></td><td>Overdominant model</td><td>G/T</td><td>1.1</td><td>(0.85–1.42)</td><td>0.48</td><td>0.94</td><td>(0.71–1.26)</td><td>0.69</td></tr><tr><td></td><td>Log - additive model</td><td>–</td><td>1.07</td><td>(0.87–1.32)</td><td>0.53</td><td>1.05</td><td>(0.83–1.32)</td><td>0.7</td></tr><tr><td>rs3824999</td><td>Allele model</td><td>C/A</td><td>0.94</td><td>(0.80–1.10)</td><td>0.432</td><td>1.14</td><td>(0.95–1.35)</td><td>0.151</td></tr><tr><td></td><td>Overdominant model</td><td>C/A</td><td>0.81</td><td>(0.64–1.04)</td><td>0.1</td><td>0.98</td><td>(0.75–1.28)</td><td>0.9</td></tr><tr><td></td><td>Log - additive model</td><td>–</td><td>0.92</td><td>(0.77–1.10)</td><td>0.37</td><td>1.13</td><td>(0.93–1.37)</td><td>0.21</td></tr><tr><td>rs3802842</td><td>Allele model</td><td>C/A</td><td>1.02</td><td>(0.88–1.20)</td><td>0.774</td><td>1.19</td><td>(1.00–1.40)</td><td>0.541</td></tr><tr><td></td><td>Overdominant model</td><td>C/A</td><td>0.99</td><td>(0.77–1.26)</td><td>0.91</td><td>1.09</td><td>(0.84–1.42)</td><td>0.52</td></tr><tr><td></td><td>Log - additive model</td><td>–</td><td>0.96</td><td>(0.81–1.14)</td><td>0.68</td><td>1.14</td><td>(0.94–1.37)</td><td>0.18</td></tr></table> |
b2d99daf2b609439d6ba5ac9ff58b332385d6f7f56fd9dd169422df5b09f96bb.png | complex | <table><tr><td rowspan="2" colspan="2">P<sub>C</sub> (%)</td><td colspan="7">Δb<sub>x</sub></td></tr><tr><td>−3km</td><td>−2km</td><td>−1km</td><td>0km</td><td>1km</td><td>2km</td><td>3km</td></tr><tr><td rowspan="7">Δ<i>b<sub>y</sub></i></td><td>-3 km</td><td>96.87</td><td>97.16</td><td>96.63</td><td>97.23</td><td>97.48</td><td>97.55</td><td>97.09</td></tr><tr><td>-2 km</td><td>96.85</td><td>96.86</td><td>97.03</td><td>97.23</td><td>97.26</td><td>97.10</td><td>97.06</td></tr><tr><td>-1 km</td><td>97.21</td><td>96.80</td><td>96.37</td><td>96.91</td><td>96.62</td><td>96.95</td><td>97.00</td></tr><tr><td>0 km</td><td>97.43</td><td>97.37</td><td>96.79</td><td>97.24</td><td>97.26</td><td>97.43</td><td>96.95</td></tr><tr><td>1 km</td><td>97.19</td><td>97.04</td><td>97.67</td><td>97.52</td><td>97.11</td><td>97.16</td><td>97.17</td></tr><tr><td>2 km</td><td>97.07</td><td>97.20</td><td>97.17</td><td>96.90</td><td>97.62</td><td>97.67</td><td>97.32</td></tr><tr><td>3 km</td><td>97.26</td><td>97.08</td><td>97.28</td><td>96.88</td><td>97.19</td><td>97.17</td><td>97.11</td></tr></table> |
bfdfb324f51f3912f5670deb809e6588897d1bec47e3d681f437956ab595e4e6.png | simple | <table><tr><td></td><td>Control(n=8)</td><td>NE(n=8)</td></tr><tr><td> Body </td><td> 40.4±1.84 </td><td> 36.4±1.28* </td></tr><tr><td> Brain </td><td> 1.31±0.11 </td><td> 1.27±0.08 NS </td></tr><tr><td> Cerebellum </td><td> 0.164±0.010 </td><td> 0.155±0.012 NS </td></tr></table> |
f6742cc9690517a6cb8afedc9b2feaaba4ab800769d5f96df05c71c3db38e464.png | complex | <table><tr><td></td><td colspan="3">Wild-Type Sibling</td><td colspan="4">Mutant</td></tr><tr><td>Gene</td><td>Control</td><td>200 μM Neomycin</td><td>% HCs Remaining</td><td colspan="2">Control</td><td>200 μM Neomycin</td><td>% HCs Remaining</td></tr><tr><td>Ciliary axoneme and intraflagellar transport</td><td></td><td></td><td></td><td colspan="2"></td><td></td><td></td></tr><tr><td rowspan="2"><i> dync2h1 (w46)</i></td><td rowspan="2">12.13 ± 1.15</td><td rowspan="2">1.05 ± 0.33</td><td rowspan="2">8.65</td><td colspan="2">8.65 ± 1.27</td><td>5.63 ± 1.26</td><td rowspan="2">65.13</td></tr><tr><td colspan="2"><i>P</i> < 0.0001</td><td><i>P</i> < 0.0001</td></tr><tr><td rowspan="2"><i> wdr35 (w150)</i></td><td rowspan="2">11.37 ± 0.92</td><td rowspan="2">1.84 ± 0.63</td><td rowspan="2">16.18</td><td colspan="2">10.10 ± 0.89</td><td>6.17 ± 1.41</td><td rowspan="2">61.89</td></tr><tr><td colspan="2"><i>P</i> = 0.0002</td><td><i>P</i> < 0.0001</td></tr><tr><td rowspan="2"><i> ift88 (tz288)</i></td><td rowspan="2">12.38 ± 1.78</td><td rowspan="2">1.17 ± 0.71</td><td rowspan="2">9.42</td><td colspan="2">9.27 ± 0.65</td><td>4.43 ± 1.70</td><td rowspan="2">47.74</td></tr><tr><td colspan="2"><i>P</i> < 0.0001</td><td><i>P</i> < 0.0001</td></tr><tr><td rowspan="2"><i> traf3ip1 (tp49d)</i></td><td rowspan="2">11.6 ± 1.43</td><td rowspan="2">1.08 ± 0.55</td><td rowspan="2">9.34</td><td colspan="2">6.73 ± 0.79</td><td>4.78 ± 0.69</td><td rowspan="2">71.04</td></tr><tr><td colspan="2"><i>P</i> < 0.0001</td><td><i>P</i> < 0.0001</td></tr><tr><td rowspan="2"><i> arl13b (hi459Tg)</i></td><td rowspan="2">11.78 ± 1.54</td><td rowspan="2">1.65 ± 0.85</td><td rowspan="2">14.00</td><td colspan="2">11.92 ± 1.01</td><td>1.30 ± 0.37</td><td rowspan="2">10.88</td></tr><tr><td colspan="2"><i>P</i> = 0.9556</td><td><i>P</i> = 0.7145</td></tr><tr><td>Transition zone</td><td></td><td></td><td></td><td colspan="2"></td><td></td><td></td></tr><tr><td rowspan="2"><i> cc2d2a (w38)</i></td><td rowspan="2">11.10 ± 1.72</td><td rowspan="2">1.53 ± 0.69</td><td rowspan="2">13.78</td><td colspan="2">12.33 ± 1.93</td><td>3.68 ± 0.47</td><td rowspan="2">29.85</td></tr><tr><td colspan="2"><i>P</i> = 0.0975</td><td><i>P</i> = 0.0023</td></tr><tr><td rowspan="2"><i> cc2d2a (w123)</i></td><td rowspan="2">12.78 ± 2.5</td><td rowspan="2">1.17 ± 0.38</td><td rowspan="2">9.13</td><td colspan="2">12.73 ± 2.24</td><td>3.05 ± 0.48</td><td rowspan="2">23.95</td></tr><tr><td colspan="2"><i>P</i> = 0.9973</td><td><i>P</i> = 0.0373</td></tr><tr><td rowspan="2"><i> mks1 (w152)</i></td><td rowspan="2">12.34 ± 0.86</td><td rowspan="2">1.26 ± 0.46</td><td rowspan="2">10.21</td><td colspan="2">12.17 ± 0.83</td><td>2.88 ± 0.65</td><td rowspan="2">23.66</td></tr><tr><td colspan="2"><i>P</i> = 0.6768</td><td><i>P</i> < 0.0001</td></tr><tr><td rowspan="2"><i> cep290 (fh378)</i></td><td rowspan="2">12.30 ± 1.02</td><td rowspan="2">1.44 ± 0.34</td><td rowspan="2">11.70</td><td colspan="2">12.19 ± 1.04</td><td>2.24 ± 0.88</td><td rowspan="2">18.34</td></tr><tr><td colspan="2"><i>P</i> = 0.7217</td><td><i>P</i> = 0.0244</td></tr></table> |
9fe2ed6c901b68f7a3ba4968f80b05231ec694b04aa79e3e8700f0a28f94d9fc.png | simple | <table><tr><td>Antimicrobial resistance pattern</td><td><i>S. flexneri</i> (6)</td><td><i>S. dysenteriae</i> (4)</td><td><i>S. boydii</i> (2)</td></tr><tr><td>AMP-AMC-CHL-CMX-STR</td><td>1(16.7)</td><td></td><td></td></tr><tr><td>AMP-CHL-CMX-STR-TET</td><td>1(16.7)</td><td>1(25)</td><td>2(100)</td></tr><tr><td>AMP-CHL-CMX-STR</td><td>3(50)</td><td>1(75)</td><td></td></tr><tr><td>AMP-CHL-CMX</td><td>1(16.7)</td><td></td><td></td></tr></table> |
71f06025e45a5bb66cc0a14778fb31efc430eed6768ea876472efb1150fbba2f.png | complex | <table><tr><td rowspan="2">Pretreatment</td><td colspan="4">Sample Point</td><td>Total Isolates</td></tr><tr><td>Point 1</td><td>Point 2</td><td>Point 3</td><td>Point 4</td><td></td></tr><tr><td>S</td><td>35/5</td><td>55/0</td><td>22/0</td><td>47/4</td><td>159/9</td></tr><tr><td>C</td><td>34/6</td><td>34/2</td><td>36/1</td><td>40/4</td><td>144/13</td></tr><tr><td>F</td><td>51/12</td><td>46/1</td><td>32/4</td><td>29/3</td><td>158/20</td></tr><tr><td>M</td><td>47/11</td><td>57/3</td><td>24/0</td><td>37/3</td><td>165/17</td></tr><tr><td>U</td><td>43/10</td><td>41/3</td><td>26/1</td><td>33/4</td><td>143/18</td></tr><tr><td>T</td><td>4/0</td><td>3/0</td><td>3/0</td><td>11/1</td><td>21/1</td></tr><tr><td rowspan="2">Total Isolates</td><td rowspan="2">214/44</td><td rowspan="2">236/9</td><td rowspan="2">143/6</td><td rowspan="2">197/19</td><td rowspan="2">790/78</td></tr></table> |
f4be14148be9bafa5d7b56d8b268b4d255d923c39023512deaee444d6e516b70.png | simple | <table><tr><td>Species/Serotypes</td><td>nb</td><td>Strains (source)</td><td>Species/Serotypes</td><td>nb</td><td>Strains (source)</td></tr><tr><td><i>Enterobacter sakazakii</i></td><td>35</td><td>ATCC 29544 (CIP)</td><td><i>Salmonella </i>Hadar</td><td>2</td><td>(AFSSA)</td></tr><tr><td></td><td></td><td>CIP 104951 (CIP)</td><td><i>Salmonella </i>Typhimurium</td><td>2</td><td>(AFSSA, BgVV)</td></tr><tr><td></td><td></td><td>CIP 104952 (CIP)</td><td><i>Salmonella </i>Typhi</td><td>1</td><td>(AFSSA)</td></tr><tr><td></td><td></td><td>ES 1, ES 2, ES 5,</td><td><i>Salmonella </i>Kottbuss</td><td>1</td><td>(AFSSA)</td></tr><tr><td></td><td></td><td>ES 9, ES 10, ES 16,</td><td><i>Salmonella </i>Virchow</td><td>1</td><td>(AFSSA)</td></tr><tr><td></td><td></td><td>ES 17, ES 18, ES 19,</td><td><i>Salmonella </i>Derby</td><td>1</td><td>(AFSSA)</td></tr><tr><td></td><td></td><td>ES 20, ES 23, ES 28,</td><td><i>Salmonella </i>Enteritidis</td><td>2</td><td>(AFSSA, BgVV)</td></tr><tr><td></td><td></td><td>ES 29, ES 30, ES 32,</td><td><i>Salmonella </i>Bredeney</td><td>1</td><td>(BgVV)</td></tr><tr><td></td><td></td><td>ES 34, ES 37, ES 40,</td><td><i>Salmonella </i>Agona</td><td>1</td><td>(AFSSA)</td></tr><tr><td></td><td></td><td>ES 41, ES 44, ES 52,</td><td><i>Salmonella </i>Indiana</td><td>1</td><td>(AFSSA)</td></tr><tr><td></td><td></td><td>ES 53 (IFF)</td><td><i>Salmonella </i>Saintpaul</td><td>1</td><td>(AFSSA)</td></tr><tr><td></td><td></td><td>ES8110043 (BM)</td><td><i>Salmonella </i>Montevideo</td><td>1</td><td>(AFSSA)</td></tr><tr><td></td><td></td><td>ES8311015 (BM)</td><td><i>Salmonella </i>Anatum</td><td>1</td><td>(AFSSA)</td></tr><tr><td></td><td></td><td>ES8704047 (BM)</td><td><i>Salmonella </i>Dublin</td><td>1</td><td>(BgVV)</td></tr><tr><td></td><td></td><td>ATCC 51329 (BM)</td><td><i>Salmonella </i>(II)</td><td>1</td><td>(BgVV)</td></tr><tr><td></td><td></td><td>ES8405628 (BM)</td><td><i>Salmonella </i>Senftenberg</td><td>1</td><td>(AFSSA)</td></tr><tr><td></td><td></td><td>ES810726 (BM)</td><td><i>Salmonella </i>(IIIa)</td><td>1</td><td>(AFSSA)</td></tr><tr><td></td><td></td><td>HMPL118 (AFSSA)</td><td><i>Salmonella </i>(IIIb)</td><td>1</td><td>(BgVV)</td></tr><tr><td></td><td></td><td>HMPL194 (AFSSA)</td><td><i>Salmonella </i>Arizonae</td><td>1</td><td>(AFSSA)</td></tr><tr><td></td><td></td><td>HMPL1937 (AFSSA)</td><td><i>Serratia fonticola</i></td><td>1</td><td>CIP 78.64 (CIP)</td></tr><tr><td></td><td></td><td>HMPL1740 (AFSSA)</td><td><i>Serratia liquefaciens</i></td><td>4</td><td>(CTSCCV, AFSSA)</td></tr><tr><td><i>Enterobacter gergoviae</i></td><td>1</td><td>ATCC 33028 (CIP)</td><td><i>Serratia marcescens</i></td><td>3</td><td>(AFSSA)</td></tr><tr><td><i>Enterobacter hormaechei</i></td><td>1</td><td>ATCC 49162 (CIP)</td><td><i>Raoultella planticola</i></td><td>1</td><td>CIP 81.36 (CIP)</td></tr><tr><td><i>Enterobacter kobei</i></td><td>1</td><td>ATCC BAA-260 (CIP)</td><td><i>Yersinia enterocolitica</i></td><td>2</td><td>(AFSSA)</td></tr><tr><td><i>Enterobacter pyrinus</i></td><td>1</td><td>ATCC 49851 (CIP)</td><td><i>Aeromonas putrefaciens</i></td><td>1</td><td>(AFSSA)</td></tr><tr><td><i>Enterobacter sp.</i></td><td>1</td><td>CIP 53.120 (CIP)</td><td><i>Aeromonas hydrophila</i></td><td>1</td><td>(AFSSA)</td></tr><tr><td><i>Enterobacter amnigenus</i></td><td>4</td><td>(CTSCCV, AFSSA)</td><td><i>Acinetobacter sp.</i></td><td>1</td><td>(AFSSA)</td></tr><tr><td><i>Enterobacter cloacae</i></td><td>18</td><td>(AFSSA)</td><td><i>Acinetobacter baumanii</i></td><td>1</td><td>CIP 70.34 (CIP)</td></tr><tr><td><i>Enterobacter aerogenes</i></td><td>5</td><td>(AFSSA)</td><td><i>Acinetobacter johnsonii</i></td><td>1</td><td>(AFSSA)</td></tr><tr><td><i>Enterobacter agglomerans</i></td><td>4</td><td>(AFSSA)</td><td><i>Acinetobacter lwoffii</i></td><td>1</td><td>CIP 104272 (CIP)</td></tr><tr><td><i>Enterobacter intermedius</i></td><td>3</td><td>(AFSSA)</td><td><i>Pseudomonas fluorescens</i></td><td>2</td><td>(AFSSA)</td></tr><tr><td><i>Citrobacter freundii</i></td><td><sup>8</sup></td><td>(AFSSA)</td><td><i>Pseudomonas aeruginosa</i></td><td>2</td><td>(AFSSA)</td></tr><tr><td><i>Citrobacter koseri</i></td><td>6</td><td>i.e. ATCC 27028 (CIP, AFSSA)</td><td><i>Stenotrophomonas maltophilia</i></td><td>1</td><td>(AFSSA)</td></tr><tr><td><i>Citrobacter sp.</i></td><td>1</td><td>(AFSSA)</td><td><i>Campylobacter jejuni</i></td><td>2</td><td>CCUG 11284</td></tr><tr><td><i>Citrobacter farmeri</i></td><td>1</td><td>(AFSSA)</td><td><i>Alcaligenes tolerans</i></td><td>1</td><td>CIP55.94 (CIP)</td></tr><tr><td><i>Escherichia coli </i>(i.e. O86; O127:H6; O157:H7; O55; O145; O113:H2; O103)</td><td>12</td><td>i.e. NCTC12900 (AFSSA)</td><td><i>Alcaligenes faecalis</i></td><td>1</td><td>CIP62.32 (CIP)</td></tr><tr><td></td><td></td><td></td><td><i>Listeria monocytogenes</i></td><td>5</td><td>i.e. clip 74902 (CIP, AFSSA)</td></tr><tr><td><i>Escherichia vulneris</i></td><td>1</td><td>(AFSSA)</td><td><i>Listeria innocua</i></td><td>1</td><td>(AFSSA)</td></tr><tr><td><i>Escherichia hermanii</i></td><td>1</td><td>(AFSSA)</td><td><i>Listeria weshimeri</i></td><td>1</td><td>ATCC 35897</td></tr><tr><td><i>Escherichia fergusonnii</i></td><td>1</td><td>(AFSSA)</td><td><i>Listeria seeligeri</i></td><td>1</td><td>Clip 12513 (CIP)</td></tr><tr><td><i>Buttiauxella agrestis</i></td><td>1</td><td>(AFSSA)</td><td><i>Listeria ivanovii</i></td><td>1</td><td>Clip 74915 (CIP)</td></tr><tr><td><i>Hafnia alvei</i></td><td>5</td><td>(AFSSA)</td><td><i>Enterococcus faecalis</i></td><td>2</td><td>(AFSSA)</td></tr><tr><td><i>Klebsiella pneumoniae</i></td><td>8</td><td>ATCC 13883</td><td><i>Enterococcus faecium</i></td><td>1</td><td>(AFSSA)</td></tr><tr><td><i>Klebsiella terrigena</i></td><td>1</td><td>(CTSCCV)</td><td><i>Bacillus cereus</i></td><td>4</td><td>(AFSSA)</td></tr><tr><td><i>Klebsiella oxytoca</i></td><td>3</td><td>(AFSSA)</td><td><i>Bacillus subtilis</i></td><td>1</td><td>CIP52.65 (CIP)</td></tr><tr><td><i>Morganella. morganii</i></td><td>1</td><td>(AFSSA)</td><td><i>Bacillus megaterium</i></td><td>1</td><td>(AFSSA)</td></tr><tr><td><i>Pantoea sp.</i></td><td>3</td><td>(AFSSA)</td><td><i>Bacillus lentus</i></td><td>1</td><td>(AFSSA)</td></tr><tr><td><i>Pantoea agglomerans</i></td><td>1</td><td>ATCC 27155</td><td><i>Staphylococcus aureus</i></td><td>3</td><td>i.e. ATCC 700699</td></tr><tr><td><i>Providencia alcalifaciens</i></td><td>1</td><td>(AFSSA)</td><td><i>Staphylococcus haemolyticus</i></td><td>1</td><td>CIP 81.56 (CIP)</td></tr><tr><td><i>Providencia stuartii</i></td><td>1</td><td>(AFSSA)</td><td><i>Staphylococcus simulans</i></td><td>1</td><td>CIP 81.64 (CIP)</td></tr><tr><td><i>Proteus vulgaris</i></td><td>2</td><td>(AFSSA)</td><td><i>Staphylococcus lentus</i></td><td>1</td><td>CIP 81.63 (CIP)</td></tr><tr><td><i>Proteus morganii</i></td><td>3</td><td>(AFSSA)</td><td><i>Staphylococcus equorum</i></td><td>1</td><td>CIP 103502 (CIP)</td></tr><tr><td><i>Proteus mirabilis</i></td><td>2</td><td>(AFSSA)</td><td><i>Staphylococcus capitis</i></td><td>1</td><td>CIP 81.53 (CIP)</td></tr><tr><td><i>Photorhabdus luminescens</i></td><td>1</td><td>TTO1 (CIP)</td><td><i>Streptococcus dysgalactiae</i></td><td>1</td><td>CIP 102914 (CIP)</td></tr><tr><td><i>Shigella sonnei</i></td><td>2</td><td>(AFSSA)</td><td><i>Streptococcus equinus</i></td><td>1</td><td>CIP 103232 (CIP)</td></tr><tr><td><i>Shigella flexneri</i></td><td>1</td><td>ATCC 12022</td><td><i>Streptococcus bovis</i></td><td>1</td><td>CIP 102302 (CIP)</td></tr></table> |
dcd26f6829151b579f32478cdd669690ed8b0176840cab44b97b43a585d24b0d.png | simple | <table><tr><td>Trait</td><td>Day 0</td><td>Day 1</td><td>Day 3</td><td>Day 7</td><td><i>P</i></td></tr><tr><td>pH</td><td>6.43 (0.20)<sup>#</sup></td><td>5.55 (0.13)</td><td>-</td><td>-</td><td> </td></tr><tr><td>Conductivity</td><td>-</td><td>6.50 (3.05)</td><td>10.75 (2.65)</td><td>11.55 (2.44)</td><td>0.10</td></tr><tr><td>CIE L*</td><td>-</td><td>55.42 (2.01)</td><td>54.80 (2.62)</td><td>54.43 (3.95)</td><td>0.73</td></tr><tr><td>CIE a*</td><td>-</td><td>7.32 (0.67)</td><td>9.63 (3.71)</td><td>9.34 (2.08)</td><td>0.27</td></tr><tr><td>CIE b*</td><td>-</td><td>15.43 (0.48)<sup>a</sup></td><td>15.53 (0.46)<sup>a</sup></td><td>16.74 (1.12)<sup>b</sup></td><td><i>0.02</i></td></tr><tr><td>Cook Loss (%)</td><td>-</td><td>33.49 (3.40)<sup>a</sup></td><td>32.42 (2.62)<sup>a,b</sup></td><td>29.86 (3.93)<sup>b</sup></td><td><i>0.05</i></td></tr><tr><td>Drip Loss (%) Day 1-3</td><td>-</td><td>-</td><td>3.91 (0.38)<sup>@</sup></td><td>-</td><td> </td></tr><tr><td>WBSF (N)</td><td>-</td><td>45.67 (3.16)<sup>a</sup></td><td>40.31 (5.20)<sup>a</sup></td><td>32.01 (3.50)<sup>b</sup></td><td><i>0.002</i></td></tr><tr><td>Intramuscular fat (%)</td><td>-</td><td>0.8 (0.4)</td><td>-</td><td>-</td><td> </td></tr></table> |
409fb7810a77c57dda8714050ed70b1c5540400c34ccc67b52f2ceaebfc65435.png | simple | <table><tr><td>Classification</td><td>Mutations and Relative Frequency</td></tr><tr><td>Congenital nevi</td><td>NRAS > BRAF</td></tr><tr><td>Spitz nevi</td><td>HRAS > BRAF > NRAS</td></tr><tr><td>Acquired nevi</td><td>BRAF > NRAS</td></tr><tr><td>Blue nevi</td><td>GNAQ > BRAF</td></tr></table> |
48414eedc924cdbd35f3bf44c6c77cb4eaa9b468d446e63faf238a3a1b025965.png | complex | <table><tr><td>Variables</td><td>Mean</td><td>Std. Dev.</td><td>Min</td><td>Max</td></tr><tr><td colspan="5">Health outcome variables for men</td></tr><tr><td> Diabetes rate (%)</td><td>2.11</td><td>2.34</td><td>0.00</td><td>14.36</td></tr><tr><td> Obesity rate (%)</td><td>11.45</td><td>7.92</td><td>1.10</td><td>36.73</td></tr><tr><td> Hypertension rate (%)</td><td>24.18</td><td>9.46</td><td>7.99</td><td>46.20</td></tr><tr><td> Average age</td><td>44.86</td><td>3.42</td><td>37.76</td><td>55.24</td></tr><tr><td colspan="5">Health outcome variables for women</td></tr><tr><td> Diabetes rate (%)</td><td>2.31</td><td>2.41</td><td>0.00</td><td>14.73</td></tr><tr><td> Obesity rate (%)</td><td>14.62</td><td>9.02</td><td>0.93</td><td>38.30</td></tr><tr><td> Hypertension rate (%)</td><td>20.22</td><td>7.82</td><td>3.67</td><td>42.12</td></tr><tr><td> Average age</td><td>42.54</td><td>2.84</td><td>36.21</td><td>50.86</td></tr></table> |
7a86c306dc8b853df7626ee288d011edba65ef54622aff7fd6c3606352ae49ad.png | complex | <table><tr><td rowspan="3">Characteristic</td><td rowspan="3">No.</td><td colspan="3">RECQL protein expression</td><td colspan="2"></td></tr><tr><td colspan="2">Low</td><td colspan="2">High</td><td rowspan="2">p</td></tr><tr><td>No.</td><td>%</td><td>No.</td><td>%</td></tr><tr><td>Total</td><td>322</td><td>133</td><td>41.3</td><td>189</td><td>58.7</td><td></td></tr><tr><td>Age</td><td></td><td></td><td></td><td></td><td></td><td></td></tr><tr><td>≤ 50 yr</td><td>153</td><td>74</td><td>54.4</td><td>82</td><td>43.4</td><td>0.07</td></tr><tr><td>> 50 yr</td><td>169</td><td>62</td><td>45.6</td><td>107</td><td>56.6</td><td></td></tr><tr><td>Tumor size</td><td></td><td></td><td></td><td></td><td></td><td></td></tr><tr><td>≤ 2 cm</td><td>112</td><td>48</td><td>45.7</td><td>64</td><td>43.5</td><td>0.73</td></tr><tr><td>> 2 cm</td><td>140</td><td>57</td><td>54.3</td><td>83</td><td>56.5</td><td></td></tr><tr><td> Unknown</td><td>70</td><td>28</td><td></td><td>42</td><td></td><td></td></tr><tr><td>Lymph node status</td><td></td><td></td><td></td><td></td><td></td><td></td></tr><tr><td> Negative</td><td>168</td><td>75</td><td>59.1</td><td>93</td><td>51.1</td><td>0.17</td></tr><tr><td> Positive</td><td>141</td><td>52</td><td>40.9</td><td>89</td><td>48.9</td><td></td></tr><tr><td> Unknown</td><td>13</td><td>6</td><td></td><td>7</td><td></td><td></td></tr><tr><td>ER status</td><td></td><td></td><td></td><td></td><td></td><td></td></tr><tr><td> Negative</td><td>100</td><td>44</td><td>43.6</td><td>56</td><td>35.9</td><td>0.22</td></tr><tr><td> Positive</td><td>157</td><td>57</td><td>56.4</td><td>100</td><td>64.1</td><td></td></tr><tr><td> Unknown</td><td>65</td><td>30</td><td></td><td>33</td><td></td><td></td></tr><tr><td>PR status</td><td></td><td></td><td></td><td></td><td></td><td></td></tr><tr><td> Negative</td><td>101</td><td>33</td><td>33.3</td><td>68</td><td>43.3</td><td>0.11</td></tr><tr><td>Positive</td><td>155</td><td>66</td><td>66.7</td><td>89</td><td>56.7</td><td></td></tr><tr><td> Unknown</td><td>66</td><td>34</td><td></td><td>32</td><td></td><td></td></tr><tr><td>HER2 status</td><td></td><td></td><td></td><td></td><td></td><td></td></tr><tr><td> Negative</td><td>233</td><td>98</td><td>78.4</td><td>135</td><td>78.0</td><td>0.94</td></tr><tr><td> Positive</td><td>65</td><td>27</td><td>21.6</td><td>38</td><td>22.0</td><td></td></tr><tr><td> Unknown</td><td>24</td><td>8</td><td></td><td>16</td><td></td><td></td></tr><tr><td>TN</td><td></td><td></td><td></td><td></td><td></td><td></td></tr><tr><td> Yes</td><td>29</td><td>7</td><td>7.8</td><td>22</td><td>14.8</td><td>0.19</td></tr><tr><td> No</td><td>210</td><td>83</td><td>92.2</td><td>127</td><td>85.2</td><td></td></tr><tr><td> Unknown</td><td>83</td><td>43</td><td></td><td>40</td><td></td><td></td></tr><tr><td>Adjuvant Therapy</td><td></td><td></td><td></td><td></td><td></td><td></td></tr><tr><td> C</td><td>124</td><td>58</td><td>43.6</td><td>66</td><td>34.9</td><td>0.463</td></tr><tr><td> E</td><td>20</td><td>7</td><td>5.3</td><td>13</td><td>6.9</td><td></td></tr><tr><td> C + E</td><td>147</td><td>56</td><td>42.1</td><td>91</td><td>48.1</td><td></td></tr><tr><td> No therapy</td><td>31</td><td>12</td><td>9.0</td><td>19</td><td>10.1</td><td></td></tr></table> |
945f5f980cff81c80542eae37bb3937a30b62e87eedb83ebe777e9dd7babdc3b.png | complex | <table><tr><td></td><td colspan="3">Before multiple imputation</td><td colspan="3">After multiple imputation</td></tr><tr><td></td><td>Model 1</td><td>Model 2</td><td>Model 3</td><td>Model 1</td><td>Model 2</td><td>Model 3</td></tr><tr><td>Intercept</td><td>0.05 (0.02)‡</td><td>0.02 (0.01)‡</td><td>0.01 (0.01)‡</td><td>0.04 (0.02)‡</td><td>0.02 (0.01)‡</td><td>0.01 (0.01)‡</td></tr><tr><td>Household-level variables</td><td></td><td></td><td></td><td></td><td></td><td></td></tr><tr><td> Residential areas</td><td></td><td></td><td></td><td></td><td></td><td></td></tr><tr><td>(Rural)</td><td></td><td></td><td></td><td></td><td></td><td></td></tr><tr><td>Urban</td><td>1.12 (0.04)‡</td><td>1.13 (0.05)‡</td><td>1.13 (0.05)‡</td><td>1.13 (0.04)‡</td><td>1.12 (0.05)‡</td><td>1.12 (0.05)‡</td></tr><tr><td> Birth attendants</td><td></td><td></td><td></td><td></td><td></td><td></td></tr><tr><td>(Non-health professional)</td><td></td><td></td><td></td><td></td><td></td><td></td></tr><tr><td>Health professional</td><td>1.53 (0.06)‡</td><td>1.52 (0.06)‡</td><td>1.53 (0.06)‡</td><td>1.57 (0.06)‡</td><td>1.57 (0.06)‡</td><td>1.56 (0.06)‡</td></tr><tr><td> Mothers’ employment status</td><td></td><td></td><td></td><td></td><td></td><td></td></tr><tr><td>(Unemployed)</td><td></td><td></td><td></td><td></td><td></td><td></td></tr><tr><td>Employed</td><td>0.96 (0.03)</td><td>0.97 (0.03)</td><td>0.96 (0.03)</td><td>0.94 (0.03)</td><td>0.94 (0.03)</td><td>0.94 (0.03)*</td></tr><tr><td> Mothers’ age</td><td></td><td></td><td></td><td></td><td></td><td></td></tr><tr><td>(≤20 years)</td><td></td><td></td><td></td><td></td><td></td><td></td></tr><tr><td>21–30 years</td><td>1.13 (0.07)†</td><td>1.14 (0.07)†</td><td>1.13 (0.07)†</td><td>1.14 (0.07)†</td><td>1.14 (0.07)†</td><td>1.14 (0.07) †</td></tr><tr><td>>30 years</td><td>1.14 (0.07)†</td><td>1.14 (0.07)†</td><td>1.14 (0.07)†</td><td>1.14 (0.07)†</td><td>1.14 (0.07)†</td><td>1.14 (0.07)†</td></tr><tr><td> Mothers’ education</td><td></td><td></td><td></td><td></td><td></td><td></td></tr><tr><td>(Primary or less)</td><td></td><td></td><td></td><td></td><td></td><td></td></tr><tr><td>Secondary</td><td>1.19 (0.04)‡</td><td>1.19 (0.04)‡</td><td>1.20 (0.04)‡</td><td>1.19 (0.04)‡</td><td>1.19 (0.04)‡</td><td>1.19 (0.04)‡</td></tr><tr><td>Higher</td><td>1.36 (0.08)‡</td><td>1.35 (0.08)‡</td><td>1.36 (0.08)‡</td><td>1.35 (0.08)‡</td><td>1.35 (0.08)‡</td><td>1.35 (0.08)‡</td></tr><tr><td>Log households income</td><td>1.20 (0.04)‡</td><td>1.20 (0.04)‡</td><td>1.20 (0.04)‡</td><td>1.22 (0.04)‡</td><td>1.20 (0.04)‡</td><td>1.22 (0.04)‡</td></tr><tr><td>District-level variables</td><td></td><td></td><td></td><td></td><td></td><td></td></tr><tr><td>Local health expenditure as a proportion of total expenditure (%)</td><td></td><td>7.68 (12.03)</td><td></td><td></td><td>8.56 (14.40)</td><td></td></tr><tr><td>Hospitals/1,000 population</td><td></td><td></td><td>0.52 (1.16)</td><td></td><td></td><td>0.44 (1.02)</td></tr><tr><td>Health centres/1,000 population</td><td></td><td></td><td>0.65 (0.18)</td><td></td><td></td><td>0.64 (0.18)</td></tr><tr><td>Village health posts/1,000 population</td><td></td><td></td><td>1.71 (0.16)‡</td><td></td><td></td><td>1.88 (0.18)‡</td></tr><tr><td>Proportion of urban population</td><td></td><td>1.68 (0.39)†</td><td>2.10 (0.59)‡</td><td></td><td>1.91 (0.46)‡</td><td>2.47 (0.71)‡</td></tr><tr><td>Population density</td><td></td><td>0.99 (0.00)‡</td><td>0.99 (0.00)†</td><td></td><td>0.99 (0.00)‡</td><td>0.99 (0.00)†</td></tr><tr><td>Log GDP per capita</td><td></td><td>0.87 (0.06)*</td><td>0.88 (0.06)*</td><td></td><td>0.93 (0.71)</td><td>0.92 (0.07)*</td></tr><tr><td>Between district variance</td><td>1.09</td><td>1.05</td><td>1.01</td><td>1.20</td><td>1.20</td><td>1.10</td></tr><tr><td>ICC</td><td>0.25</td><td>0.24</td><td>0.23</td><td>0.27</td><td>0.27</td><td>0.25</td></tr><tr><td>MOR</td><td>2.71</td><td>2.65</td><td>2.61</td><td>2.85</td><td>2.84</td><td>2.72</td></tr></table> |
c9bc985a9882c6d25d7c4615247bba759b1c02e327a55d1583a6551c63e1eec5.png | complex | <table><tr><td>Demographic characteristic</td><td>Frequency</td><td>%</td></tr><tr><td colspan="3">Campus location</td></tr><tr><td>Site 1</td><td>47</td><td>18.7</td></tr><tr><td>Site 2</td><td>205</td><td>81.3</td></tr><tr><td colspan="3">Year of study</td></tr><tr><td>Year 2</td><td>184</td><td>74.5</td></tr><tr><td>Year 3</td><td>43</td><td>17.4</td></tr><tr><td>Year 4</td><td>16</td><td>6.5</td></tr><tr><td colspan="3">Gender</td></tr><tr><td>Female</td><td>230</td><td>91.3</td></tr><tr><td>Male</td><td>22</td><td>8.7</td></tr><tr><td colspan="3">Marital status</td></tr><tr><td>Single/Divorced</td><td>205</td><td>82.0</td></tr><tr><td>Married/living with a partner</td><td>45</td><td>18.0</td></tr><tr><td colspan="3">Living arrangement</td></tr><tr><td>With the family</td><td>235</td><td>94.0</td></tr><tr><td>On campus</td><td>2</td><td>0.8</td></tr><tr><td>Off campus</td><td>13</td><td>5.2</td></tr><tr><td colspan="3">Employment status</td></tr><tr><td>Employed</td><td>28</td><td>11.1</td></tr><tr><td>Not employed</td><td>224</td><td>88.9</td></tr></table> |
c1267daf8ddab1e498525cd25d1800dbf1bf8c92ed6c183fd77caeb29595f832.png | complex | <table><tr><td></td><td colspan="3">Based on Annual Mileage: Magnusson and Colleagues [32]</td><td colspan="3">Based on Tyres Sold: Swedish National Chemicals Inspectorate [33]</td></tr><tr><td></td><td>Wear mg/km</td><td>Total Mileage in 2012 (×10<sup>6</sup> km)</td><td>Total Wear 2012 Tonnes/Year</td><td>Mass of Tyres Consumed Annually kg</td><td>Weight Loss (17%) kg</td><td>Total Wear 2002 tonnes/year</td></tr><tr><td>Passenger car</td><td>50</td><td>62,940</td><td>3147</td><td></td><td></td><td></td></tr><tr><td>Bus/lorry</td><td>700</td><td>14,416</td><td>10,091</td><td></td><td></td><td></td></tr><tr><td>Total</td><td></td><td>77,356</td><td>13,238</td><td>60,000,000</td><td>10,000,000</td><td>10,000</td></tr></table> |
24b71e032d3b00092fb2aa70b0aa1fb0d02727f48501ad4d161284e5aa174d0b.png | complex | <table><tr><td rowspan="2">Characteristics</td><td colspan="5">Often<sup>a</sup></td></tr><tr><td>n</td><td>%</td><td>OR crude</td><td>95% CI</td><td><i>p</i></td></tr><tr><td colspan="6">Self-rated health</td></tr><tr><td> Good/very good</td><td>387</td><td>18.3</td><td>1.00</td><td></td><td rowspan="3"><0.001</td></tr><tr><td> Regular</td><td>224</td><td>25.7</td><td>1.54</td><td>(1.27–1.86)</td></tr><tr><td> Poor/very poor</td><td>92</td><td>40.4</td><td>3.01</td><td>(2.26–4.02)</td></tr><tr><td colspan="6">Absenteeism in the past 12 months</td></tr><tr><td> None</td><td>358</td><td>20.8</td><td>1.00</td><td></td><td rowspan="3">0.116</td></tr><tr><td> Up to 9 days</td><td>200</td><td>22.6</td><td>1.11</td><td>(0.91–1.35)</td></tr><tr><td> 10 days or more</td><td>147</td><td>24.8</td><td>1.25</td><td>(1.00–1.56)</td></tr></table> |
1e6c472ce0d642afa38952a3035e2640d74a0af860ed8f2a1a31fac275477079.png | complex | <table><tr><td>Host</td><td colspan="2">Demographic factor</td><td>Positive animals percentage</td></tr><tr><td rowspan="7">Sheep (<i>n</i> = 189)</td><td rowspan="2">Gender</td><td>Male (128)</td><td>66 (34.9%)<sup>a</sup></td></tr><tr><td>Female (61)</td><td>20 (10.6%)</td></tr><tr><td rowspan="3">Age</td><td>Group I (84)</td><td>47 (24.9%)<sup>a</sup></td></tr><tr><td>Group II (89)</td><td>36 (19.0%)</td></tr><tr><td>Group III (16)</td><td>3 (1.6%)</td></tr><tr><td rowspan="2">Source</td><td>imported (82)</td><td>53 (28.1%)</td></tr><tr><td>Local (107)</td><td>33 (17.5%)</td></tr><tr><td rowspan="7">Goat (<i>n</i> = 123)</td><td rowspan="2">Gender</td><td>Male (65)</td><td>38 (30.9%)<sup>a</sup></td></tr><tr><td>Female (58)</td><td>12 (9.8%)</td></tr><tr><td rowspan="3">Age</td><td>Group I (44)</td><td>22 (17.9%)<sup>a</sup></td></tr><tr><td>Group II (60)</td><td>24 (19.5%)</td></tr><tr><td>Group III (19)</td><td>4 (3.3%)</td></tr><tr><td rowspan="2">Source</td><td>Imported (41)</td><td>34 (27.6%)</td></tr><tr><td>Local (82)</td><td>16 ( 13.0%)</td></tr></table> |
1c59324695140871eae050efc17b3c7741e1e8ddd79338e68d6e62fed1081c8a.png | complex | <table><tr><td>Items</td><td>Group</td><td>Villus Height (μm)</td><td>Crypt Depth (μm)</td><td>Villus Height/Crypt Depth</td></tr><tr><td rowspan="2">Jejunum</td><td>Control</td><td>1212.27 ± 47.79 <sup>a</sup></td><td>249.78 ± 12.50 <sup>a</sup></td><td>4.86 ± 0.29</td></tr><tr><td>200 mg/kg</td><td>1381.83 ± 36.21 <sup>b</sup></td><td>370.41 ± 10.03 <sup>b</sup></td><td>3.69 ± 0.37</td></tr><tr><td rowspan="2">Ileum</td><td>Control</td><td>1175.01 ± 59.35 <sup>a</sup></td><td>213.96 ± 33.02 <sup>a</sup></td><td>5.58 ± 0.56</td></tr><tr><td>200 mg/kg</td><td>1417.10 ± 75.12 <sup>b</sup></td><td>411.05 ± 45.39 <sup>b</sup></td><td>3.49 ± 0.51</td></tr></table> |
ca02c6c27ec5cf2a33f894779cbe3d2892fef7b69faaff93ef7cd6d620267a14.png | simple | <table><tr><td> </td><td>StudypopulationN=79</td><td>Aggressivesubjectsn=31</td><td>Non-aggressivesubjectsn=48</td><td>Significancep</td></tr><tr><td>Mean age </td><td>82.7±8.7</td><td>80.2±11.2</td><td>84.4±6.2</td><td>0.1</td></tr><tr><td>Sex (% female)</td><td>50 (63.3)</td><td>14 (45.2)</td><td>36 (75.0)</td><td>0.01</td></tr><tr><td>Marital status (% living alone)</td><td>50 (63.3)</td><td>15 (48.4)</td><td>35 (72.9)</td><td>0.028</td></tr><tr><td>MMSE mean±SD</td><td>17.9±7.1</td><td>15.13±7.8</td><td>19.7±5.9</td><td>0.009</td></tr><tr><td>CMAI mean±SD</td><td>46.2±22.1</td><td>63.3±25.8</td><td>35.2±8.5</td><td><0.001</td></tr><tr><td>F-RAGE mean±SD</td><td>9.3±13.1</td><td>21.7±12.9</td><td>1.2±3.1</td><td><0.001</td></tr><tr><td>NPI mean±SD</td><td>16.4±11.6</td><td>22.1±10.9</td><td>12.8±10.7</td><td><0.001</td></tr></table> |
f16891bc4c078c0cc84495e7a375827894d84f4d4b364bed04cdd8d72a67b361.png | simple | <table><tr><td></td><td>RA with MAC-PD</td><td>RA without MAC-PD</td><td>Total</td></tr><tr><td>Anti-GPL ab, positive</td><td>8</td><td>4</td><td>12</td></tr><tr><td>Anti-GPL ab, negative</td><td>2</td><td>355</td><td>357</td></tr><tr><td>Total</td><td>10</td><td>359</td><td>369</td></tr></table> |
9b3530435cae09217a0b1fef3f363b4d037e413312d6c7d43bf00a86c3877676.png | complex | <table><tr><td rowspan="2">Emergency level</td><td rowspan="2">No.</td><td>Admitted to</td><td>Admission risk,</td></tr><tr><td>hospital</td><td>% (95% CI)</td></tr><tr><td>A</td><td>28,630</td><td>18,440</td><td>64.4 (63.8-65.0)</td></tr><tr><td>B</td><td>25,419</td><td>13,190</td><td>51.9 (51.3-52.5)</td></tr><tr><td>C</td><td>1,112</td><td>475</td><td>42.7 (39.8-45.7)</td></tr><tr><td>D</td><td>109</td><td>34</td><td>31.2 (22.7-40.8)</td></tr><tr><td>All</td><td>55,270</td><td>32,139</td><td>58.1 (57.7-58.6)*</td></tr></table> |
8e6dc7aa8085a07a1f4947ee2a54a3f1206cf0b47469a906ba2f661ab1aed65a.png | simple | <table><tr><td>Variable</td><td>Coefficient</td><td>t-Statistic</td><td>p-value</td></tr><tr><td>C</td><td>0.912</td><td>9.44</td><td>0.000</td></tr><tr><td>AGE</td><td>1.78E-05</td><td>0.009</td><td>0.993</td></tr><tr><td>EDU</td><td>0.034</td><td>1.030</td><td>0.307</td></tr><tr><td>OCC</td><td>0.025</td><td>0.706</td><td>0.483</td></tr><tr><td>MASI</td><td>0.000</td><td>0.251</td><td>0.803</td></tr><tr><td>TR</td><td>0.001</td><td>0.525</td><td>0.601</td></tr><tr><td>MS</td><td>0.013</td><td>0.387</td><td>0.700</td></tr><tr><td>INC</td><td>1.40E-07</td><td>0.238</td><td>0.813</td></tr></table> |
3a341b1aa093c8b8cdaa634d2c526e92b45924be2f9ae9554dd82703d2783581.png | simple | <table><tr><td>Patient Number</td><td>Age</td><td>Gender</td><td>Tumour location</td><td>Initial MRI Dimensions (cm)</td><td>PTV volume (cm<sup>3</sup>)</td></tr><tr><td>1</td><td>29</td><td>F</td><td>L anterior chest wall</td><td>6.5 × 3.6 × 2.1</td><td>534</td></tr><tr><td>2</td><td>47</td><td>M</td><td>R posterior chest wall</td><td>10.0 × 3.5 × 5.5</td><td>2082</td></tr><tr><td>3</td><td>64</td><td>M</td><td>R anterior chest wall</td><td>6.9 × 2.6 × 3.0</td><td>767</td></tr><tr><td>4</td><td>34</td><td>F</td><td>L axilla</td><td>7.6 × 11.8 × 11.5</td><td>1017</td></tr><tr><td>5</td><td>34</td><td>M</td><td>L axilla and lateral chest wall</td><td>10.5 × 12.5 × 5.0</td><td>3896</td></tr><tr><td>6</td><td>22</td><td>M</td><td>R axilla and supraclavicular fossa</td><td>10.3 × 5.9 × 5.2</td><td>1303</td></tr><tr><td>7</td><td>46</td><td>M</td><td>R anteriolateral chest wall</td><td>15.0 × 20.0 × 6.0</td><td>4539</td></tr><tr><td>8</td><td>49</td><td>M</td><td>L anterior chest wall</td><td>8.5 × 5.6 × 6.8</td><td>950</td></tr><tr><td>9</td><td>41</td><td>F</td><td>L anterior chest wall</td><td>4.3 × 1.4 × 2.5</td><td>416</td></tr><tr><td>10</td><td>20</td><td>M</td><td>L neck and supraclavicular fossa</td><td>8.7 × 5.5 × 6.7</td><td>646</td></tr></table> |
766ead4dd05c963aa5ef900c8617dddcdae0f65ed0f98971ce4320ff6238ff02.png | simple | <table><tr><td>Site</td><td>Treatment</td><td>IRR (95%CI)</td><td>P value</td></tr><tr><td>Kilifi</td><td>Carbon dioxide only</td><td>0.57(0.21 – 1.52)</td><td>0.255</td></tr><tr><td>Kilifi</td><td>Blend 2</td><td>1.33 (0.50 -3.57)</td><td>0.552</td></tr><tr><td>Kilifi</td><td>Blend 4</td><td>0.95(0.36- 2.56)</td><td>0.931</td></tr><tr><td>Kilifi</td><td>Hexanoic acid</td><td>2.2 (0.82- 5.87)</td><td>0.109</td></tr></table> |
47641d4f3922ab355438c36cf7b0de5d858a3f523b86d6b832078c898352f155.png | simple | <table><tr><td></td><td></td><td>Mean</td><td>SD</td><td>No.</td><td>p-value</td></tr><tr><td>Items from CAD and renal failure (lecture format the same for each group)</td><td>Live lecture</td><td>4.42</td><td>1.08</td><td>12</td><td></td></tr><tr><td></td><td>CD-ROM</td><td>4.88</td><td>2.00</td><td>17</td><td></td></tr><tr><td></td><td>t-test<sup>†</sup></td><td></td><td></td><td></td><td>0.22 (one-tailed)</td></tr><tr><td></td><td>Mann Whitney U</td><td></td><td></td><td></td><td>0.56 (exact test)</td></tr><tr><td></td><td>Levene's Test for equality of variances</td><td></td><td></td><td></td><td>0.026</td></tr><tr><td>Items from other four lectures (lecture format differed for control & treatment groups)</td><td>Live lecture</td><td>9.25</td><td>3.11</td><td>12</td><td></td></tr><tr><td></td><td>CD-ROM</td><td>9.00</td><td>2.72</td><td>17</td><td></td></tr><tr><td></td><td>t-test<sup>†</sup></td><td></td><td></td><td></td><td>0.41 (one-tailed)</td></tr><tr><td></td><td>Mann Whitney U</td><td></td><td></td><td></td><td>0.91 (exact test)</td></tr><tr><td></td><td>Levene's Test for equality of variances</td><td></td><td></td><td></td><td>0.96</td></tr></table> |
2a3bace9805fc9ff3ca7d7b16fa151ee46e596d7f94c000c01c2a69d0f669459.png | simple | <table><tr><td>Drugs</td></tr><tr><td>Acetaminophen</td></tr><tr><td>Antiretroviral therapy (e.g., stavudine, zidovudine, and lamivudine)</td></tr><tr><td>β-2 agonists (e.g., salbutamol, terbutaline)</td></tr><tr><td>Biguanides (e.g., metformin, phenformin)</td></tr><tr><td>Isoniazid</td></tr><tr><td>Lactulose</td></tr><tr><td>Linezolid</td></tr><tr><td>Nalidixic acid</td></tr><tr><td>Niacin</td></tr><tr><td>Nitroprusside sodium</td></tr><tr><td>Propofol</td></tr><tr><td>Simvastatin</td></tr><tr><td>Theophylline</td></tr><tr><td>Vasoactive drugs (e.g., epinephrine, norepinephrine)</td></tr></table> |
1beda84732f8319bea512848c3704981a8380033bf2f589b3576356924d77596.png | complex | <table><tr><td rowspan="3">AVERAGE PROBABILITY</td><td colspan="4">Sensitivity</td><td colspan="4">Specificity</td><td colspan="4">AUC</td></tr><tr><td rowspan="2">Ensemble classifier</td><td colspan="3">Individual classifiers</td><td rowspan="2">Ensemble classifier</td><td colspan="3">Individual classifiers</td><td rowspan="2">Ensemble classifier</td><td colspan="3">Individual classifiers</td></tr><tr><td>min</td><td>max</td><td>average</td><td>min</td><td>max</td><td>average</td><td>min</td><td>max</td><td>average</td></tr><tr><td>Ensemble 1</td><td>0.73</td><td>0.64</td><td>0.73</td><td>0.68</td><td>0.90</td><td>0.90</td><td>0.95</td><td>0.93</td><td>0.95</td><td>0.73</td><td>0.94</td><td>0.84</td></tr><tr><td>Ensemble 2</td><td>0.82</td><td>0.55</td><td>0.82</td><td>0.69</td><td>0.95</td><td>0.86</td><td>1.00</td><td>0.93</td><td>0.98</td><td>0.73</td><td>0.96</td><td>0.88</td></tr><tr><td>Ensemble 3</td><td>0.73</td><td>0.64</td><td>0.73</td><td>0.65</td><td>0.95</td><td>0.81</td><td>0.95</td><td>0.91</td><td>0.97</td><td>0.73</td><td>0.94</td><td>0.88</td></tr><tr><td>Ensemble 4</td><td>0.82</td><td>0.55</td><td>0.73</td><td>0.64</td><td>0.90</td><td>0.81</td><td>1.00</td><td>0.92</td><td>0.97</td><td>0.83</td><td>0.95</td><td>0.90</td></tr><tr><td>Ensemble 5</td><td>0.82</td><td>0.55</td><td>0.82</td><td>0.66</td><td>0.95</td><td>0.81</td><td>1.00</td><td>0.92</td><td>0.98</td><td>0.73</td><td>0.96</td><td>0.89</td></tr></table> |
b6dfd35bc7baf4c99e36abd0fa992766575605fc7956efedea48185eed7fa673.png | complex | <table><tr><td></td><td></td><td colspan="3">Recommended or adequate treatment</td></tr><tr><td>Characteristic</td><td>No. of consultations or mean value</td><td>OR (95% CI)</td><td>n (%)</td><td>OR (95% CI)</td></tr><tr><td><i>Final multivariate models</i></td><td></td><td></td><td></td><td></td></tr><tr><td>Health worker received</td><td></td><td></td><td></td><td></td></tr><tr><td> Study supports</td><td>N = 28</td><td>3.0 (1.0, 8.6)</td><td>15 (53.6)</td><td>1.5 (0.6, 3.7)</td></tr><tr><td> Usual supports</td><td>N = 42</td><td>ref.</td><td>19 (45.2)</td><td>ref.</td></tr><tr><td>No. supervisory visits, past 6 months (ranging from 0-4)</td><td>mean = 0.9</td><td>2.1 (1.1, 3.9)</td><td>--</td><td>1.6 (1.1, 2.3)</td></tr><tr><td>Consultation duration, in minutes (ranging from 5 to 131)</td><td>median = 16</td><td>1.04 (1.00, 1.08)</td><td>--</td><td>--<sup>b</sup></td></tr><tr><td>No. of IMCI classifications(ranging from 1 to 4)</td><td>mean = 2.8</td><td>--<sup>b</sup></td><td>--</td><td>2.0 (1.2, 3.3)</td></tr><tr><td><i>Causal pathway variable omitted</i><i>from multivariate modelling</i></td><td></td><td></td><td></td><td></td></tr><tr><td>Health worker correctly diagnosed pneumonia</td><td></td><td></td><td></td><td></td></tr><tr><td> Yes</td><td>N = 49</td><td>49.8 (5.6, 442.1)</td><td>28 (68.3)</td><td>14.2 (4.0, 50.3)</td></tr><tr><td> No</td><td>N = 21</td><td>ref.</td><td>6 (20.7)</td><td>ref.</td></tr></table> |
1b3d128b8aaecb59ca4f2cdd92baa74300481a4418c43350e8dc76f9184b5aab.png | complex | <table><tr><td>Gender</td><td colspan="5">Genotype</td></tr><tr><td></td><td>A</td><td>B</td><td>C</td><td>D</td><td>Not typed</td></tr><tr><td>Male</td><td>30</td><td>9</td><td>48</td><td>45</td><td>6</td></tr><tr><td>Female</td><td>3</td><td>3</td><td>7</td><td>16</td><td>2</td></tr><tr><td>Total</td><td>33(19.53%)</td><td>12(7.10%)</td><td>55(32.54%)</td><td>61(36.09%)</td><td>8(4.73%)</td></tr></table> |
763a08cfa3c1f4cb83763688c470457ae4b649bedf378e3009a9d521a7341d32.png | simple | <table><tr><td>Semen variable</td><td>Before maca <i>N</i> = 9</td><td>After maca <i>N</i> = 9</td><td><i>P</i> value</td></tr><tr><td>Volume (mL)</td><td>2.23 ± 0.28</td><td>2.91 ± 0.28</td><td><0.05</td></tr><tr><td>pH</td><td>7.47 ± 0.09</td><td>7.44 ± 0.07</td><td>NS</td></tr><tr><td>Sperm count (10<sup>6</sup>/mL)</td><td>67.06 ± 18.61</td><td>90.33 ± 20.46</td><td>NS</td></tr><tr><td>Total sperm count (10<sup>6</sup>/mL)</td><td>140.95 ± 31.05</td><td>259.29 ± 68.17</td><td><0.05</td></tr><tr><td>Motile sperm count (10<sup>6</sup>/mL)</td><td>87.72 ± 19.87</td><td>183.16 ± 47.84</td><td><0.05</td></tr><tr><td>Sperm motility grade a (%)</td><td>29.00 ± 5.44</td><td>33.65 ± 3.05</td><td>NS</td></tr><tr><td>Sperm motility grade a + b (%)</td><td>62.11 ± 3.64</td><td>71.02 ± 2.86</td><td><0.05</td></tr><tr><td>Normal sperm morphology (%)</td><td>75.50 ± 2.02</td><td>76.90 ± 1.23</td><td>NS</td></tr></table> |
063e362196cdf73d84551812d618728600851bd073ac07a3809294938b633f97.png | complex | <table><tr><td colspan="2">Ultraviolet (UV)-Curable Resin</td></tr><tr><td>Density</td><td>0.95 mm</td></tr><tr><td>Viscosity</td><td>600 MPa·s</td></tr></table> |
760039d820299577984ff596e3e2599e805357d6534e406c3a85c0eadbe78628.png | simple | <table><tr><td></td><td>CNB</td><td>Surgical biopsy</td></tr><tr><td>Procedures/patients</td><td>66/591</td><td>20/20</td></tr><tr><td>Males/females</td><td>32/27</td><td>15/5</td></tr><tr><td>Median age (range)</td><td>63.5 (24–85)</td><td>60 (42–72)</td></tr><tr><td>>75 years old</td><td>11</td><td>0</td></tr><tr><td>Imaging modalities</td><td>CT 51 US 15</td><td>–</td></tr><tr><td>Surgical procedures</td><td>–</td><td>Laparotomy 15 Laparoscopic surgery 2</td></tr><tr><td>Sampling sites</td><td>Paraaortic LN 24 Mesenteric LN 13 Paravertebral mass 9 Retroperitoneum mass 8 Pelvic mass 6 Adrenal gland 4 Splenic LN 1 Parapancreatic mass 1</td><td>Mesenteric LN 9 Paraaortic LN 5 Retroperitoneal mass 3 Hepatic LN 1 Ext. iliac LN 1 Omentum mass 1</td></tr></table> |
fef2e742147776a91ba82a29eb79fe6b5d6843c3c32c3aa5cc4eb43a9e8379a6.png | simple | <table><tr><td>Microorganisms</td><td>ICU-A</td><td>ICU-B</td><td>ICU-C</td><td>Total</td></tr><tr><td>Gram-positive cocci</td><td>23</td><td>10</td><td>8</td><td>41</td></tr><tr><td>Coagulase-negative <i>Staphylocci</i></td><td>13</td><td>9</td><td>2</td><td>24</td></tr><tr><td><i>Staphylococcus aureus</i></td><td>9</td><td>0</td><td>4</td><td>13</td></tr><tr><td><i>Enteroccocus sp.</i></td><td>1</td><td>1</td><td>2</td><td>4</td></tr><tr><td>Gram-negative bacilli</td><td>15</td><td>1</td><td>9</td><td>25</td></tr><tr><td><i>Enterobacteriaceae</i></td><td>12</td><td>1</td><td>5</td><td>17</td></tr><tr><td>Other Gram-negative Bacilli</td><td>3</td><td>0</td><td>4</td><td>7</td></tr><tr><td>Yeasts</td><td>4</td><td>0</td><td>1</td><td>5</td></tr><tr><td>Total</td><td>42</td><td>11</td><td>18</td><td>71</td></tr></table> |
5f0d4864791b2f64b34cf968f64b27e4904bd8ce923c120143bba89c0a7b8fdf.png | simple | <table><tr><td>Dataset <sup>a</sup></td><td>KNG95</td><td>KNG01</td><td>FKO</td><td>NGY</td><td>KMM</td><td>NGN</td></tr><tr><td>Date (FY)</td><td>1995–1996</td><td>2001–2003</td><td>2003</td><td>2004</td><td>2011–2012</td><td>2013</td></tr><tr><td>Location <sup>b</sup></td><td>KNG Pref.</td><td>KNG Pref.</td><td>FKO Pref.</td><td>NGY City</td><td>KMM Pref.</td><td>NGN Pref.</td></tr><tr><td>Line <sup>c</sup></td><td>TSL</td><td>TSL</td><td>SSL</td><td>TSL</td><td>KSL</td><td>HSL</td></tr><tr><td>Number of trains <sup>d</sup></td><td></td><td></td><td></td><td></td><td></td><td></td></tr><tr><td> Daytime (7:00–22:00)</td><td>234</td><td>265</td><td>142</td><td>249</td><td>112</td><td>62</td></tr><tr><td> Nighttime (22:00–7:00)</td><td>16</td><td>22</td><td>18</td><td>21</td><td>17</td><td>7</td></tr><tr><td>Method</td><td>Visit-Mail <sup>e</sup></td><td>Visit-Mail <sup>e</sup></td><td>Visit-Mail <sup>e</sup></td><td>Interview</td><td>Visit-Visit <sup>e</sup></td><td>Mail-Mail <sup>e</sup></td></tr><tr><td>Housing type (DH; AB) <sup>f</sup></td><td>DH</td><td>DH & AB</td><td>DH</td><td>DH</td><td>DH & AB</td><td>DH</td></tr><tr><td>Annoyance</td><td>unbearable</td><td>ICBEN <sup>g</sup></td><td>ICBEN <sup>g</sup></td><td>ICBEN <sup>g</sup></td><td>ICBEN <sup>g</sup></td><td>ICBEN <sup>g</sup></td></tr><tr><td>Response proportion (%) <sup>h</sup></td><td>72</td><td>57</td><td>66</td><td>58</td><td>45</td><td>45</td></tr><tr><td>Sample size</td><td>709</td><td>872</td><td>358</td><td>175</td><td>559</td><td>294</td></tr></table> |
f118e6f8afdb0040c7217d574199c122d1ff2f8ab9de6f300910bf62317c53f1.png | simple | <table><tr><td>Country</td><td>Author</td><td>Setting</td><td>Number</td><td>Measure</td><td>Prevalence</td></tr><tr><td>Lesotho</td><td>Hollifield <i>et al.</i> 1990</td><td>Rural</td><td>356</td><td>DIS</td><td>23.5% F14.7% M</td></tr><tr><td>Zimbabawe</td><td>Abas & Broadhead, 1997</td><td>Urban</td><td>172</td><td>SSQ</td><td>15.7% F 1 month, 30.8% F 1 year</td></tr><tr><td>South Africa</td><td>Haavenaar <i>et al.</i> 2008</td><td>Periurban</td><td>209</td><td>SRQ</td><td>34.9% M and F</td></tr><tr><td>South Africa</td><td>Haavenaar <i>et al.</i> 2008</td><td>Rural</td><td>222</td><td>SRQ</td><td>27.0% M and F</td></tr><tr><td>South Africa</td><td>Hamad <i>et al.</i> 2008</td><td>Urban</td><td>257</td><td>CES-D</td><td>64.5% F, 50.4 % M</td></tr><tr><td>Nigeria</td><td>Gureje <i>et al.</i> 2006</td><td>Probability sample of 8 states</td><td>4,984</td><td>CIDI</td><td>12.1% life time; 5.8% 12 month prevalence M and F</td></tr><tr><td>Ethiopia</td><td>Tafari <i>et al.</i> 1991</td><td>Rural</td><td>2,000</td><td>SRQ</td><td>11.2% M and F</td></tr><tr><td>Uganda</td><td>Orley and Wing 1979</td><td>Rural</td><td></td><td>PSE</td><td></td></tr><tr><td>Sudan</td><td>Rahim and Cederblad</td><td>Urban</td><td></td><td>SRQ/DSM III</td><td>16.6% M and F</td></tr></table> |
69815701c7fbdd688b673bb8ad40c02d0602c2f4ed42deaf83cb162d72868b6f.png | complex | <table><tr><td><i>Test</i></td><td> </td><td><i>Positives (%)</i></td><td><i>Negatives (%)</i></td></tr><tr><td colspan="4"><i>T=3months</i></td></tr><tr><td>Culture (N=305)</td><td>Eradication</td><td>11 (7)</td><td>141 (93)</td></tr><tr><td> </td><td>Placebo</td><td>99 (65)</td><td>54 (35)</td></tr><tr><td>H&E stains (N=305)</td><td>Eradication</td><td>19 (12)</td><td>133 (88)</td></tr><tr><td> </td><td>Placebo</td><td>112 (73)</td><td>41 (27)</td></tr><tr><td>IHC stains (N=68)</td><td>Eradication</td><td>29 (85)</td><td>5 (15)</td></tr><tr><td> </td><td>Placebo</td><td>7 (20)</td><td>27 (79)</td></tr><tr><td>Serology (N=203)</td><td>Eradication</td><td>92 (91)</td><td>9 (9)</td></tr><tr><td> </td><td>Placebo</td><td>94 (92)</td><td>8 (8)</td></tr><tr><td colspan="4"><i>T=12months</i></td></tr><tr><td>Serology (N=304)</td><td>Eradication</td><td>96 (64)</td><td>55 (36)</td></tr><tr><td> </td><td>Placebo</td><td>138 (90)</td><td>15 (10)</td></tr></table> |
63d3ef0367ea0b9793c1f38edef91fe09cc6e008d32716ff00ac22339b83f2a3.png | complex | <table><tr><td>Characteristic</td><td>Normal No %</td><td>Underweight No %</td><td>Overweight No %</td><td>Obese No %</td><td>Total</td></tr><tr><td colspan="6">Social class</td></tr><tr><td>Upper</td><td>244 (84.4)</td><td>12 (4.1)</td><td>25 (8.7)</td><td>8 (2.8)</td><td>289 (100)</td></tr><tr><td>Middle</td><td>327 (86.7)</td><td>23 (6.1)</td><td>20 (5.3)</td><td>7 (1.9)</td><td>377 (100)</td></tr><tr><td>Lower</td><td>248 (84.4)</td><td>26 (8.8)</td><td>18 (6.1)</td><td>2 (0.7)</td><td>294 (100)</td></tr><tr><td colspan="6">Mother’s education</td></tr><tr><td>No education</td><td>47 (90.4)</td><td>4 (7.7)</td><td>1 (1.9)</td><td>0 (0.0)</td><td>52 (100)</td></tr><tr><td>Primary</td><td>139 (87.4)</td><td>10 (6.3)</td><td>9 (5.7)</td><td>1 (0.6)</td><td>159 (100)</td></tr><tr><td>Secondary</td><td>358 (86.1)</td><td>26 (6.3)</td><td>24 (5.8)</td><td>8 (1.9)</td><td>416 (100)</td></tr><tr><td>Technical/Commer</td><td>55 (85.9)</td><td>5 (7.8)</td><td>3 (4.7)</td><td>1 (1.6)</td><td>64 (100)</td></tr><tr><td>Higher/University</td><td>220 (81.8)</td><td>16 (5.9)</td><td>26 (9.7)</td><td>7 (2.6)</td><td>269 (100)</td></tr><tr><td colspan="6">Family size</td></tr><tr><td>≤5</td><td>198 (84.6)</td><td>19 (8.1)</td><td>13 (5.6)</td><td>4 (1.7)</td><td>234 (100)</td></tr><tr><td>6–10</td><td>563 (85.7)</td><td>36 (5.5)</td><td>45 (6.8)</td><td>13 (2.0)</td><td>657 (100)</td></tr><tr><td>11–15</td><td>58 (84.1)</td><td>6 (8.7)</td><td>5 (7.2)</td><td>0 (0.0)</td><td>69 (100)</td></tr><tr><td colspan="6">Hours spent watching TV</td></tr><tr><td>0–2</td><td>477 (86.1)</td><td>33 (6.0)</td><td>37 (6.7)</td><td>7 (1.3)</td><td>554 (100)</td></tr><tr><td>3–4</td><td>238 (85.0)</td><td>19 (6.8)</td><td>19 (6.8)</td><td>4 (1.4)</td><td>280 (100)</td></tr><tr><td>≥5</td><td>104 (82.5)</td><td>9 (7.1)</td><td>7 (5.6)</td><td>6 (4.8)</td><td>126 (100)</td></tr><tr><td colspan="6">Snack intake/week</td></tr><tr><td>Once</td><td>101 (87.1)</td><td>5 (4.3)</td><td>6 (5.2)</td><td>4 (3.4)</td><td>116 (100)</td></tr><tr><td>1–2</td><td>137 (87.3)</td><td>11 (7.0)</td><td>9 (5.7)</td><td>0 (0.0)</td><td>157 (100)</td></tr><tr><td>>3</td><td>199 (86.4)</td><td>13 (5.7)</td><td>13 (5.7)</td><td>5 (2.2)</td><td>230 (100)</td></tr><tr><td>Everyday</td><td>382 (83.5)</td><td>32 (7.0)</td><td>35 (7.7)</td><td>8 (1.8)</td><td>457 (100)</td></tr><tr><td colspan="6">Soft drink/week</td></tr><tr><td>Once</td><td>320 (84.2)</td><td>26 (6.8)</td><td>24 (6.3)</td><td>10 (2.6)</td><td>380 (100)</td></tr><tr><td>1–2 times</td><td>254 (87.0)</td><td>20 (6.8)</td><td>15 (5.1)</td><td>3 (1.0)</td><td>292 (100)</td></tr><tr><td>>3</td><td>161 (84.3)</td><td>11 (5.8)</td><td>16 (8.4)</td><td>3 (1.6)</td><td>191 (100)</td></tr><tr><td>Everyday</td><td>84 (86.6)</td><td>4 (4.1)</td><td>8 (8.2)</td><td>1 (1.0)</td><td>97 (100)</td></tr></table> |
874a03976ceb932a0666a02c3e1818d8ffe17dda7d27304dd81e4cd7da94d98c.png | simple | <table><tr><td>Hyperparameter</td><td>Value</td><td>Number of Occurrences</td></tr><tr><td>criterion</td><td>entropy</td><td>7</td></tr><tr><td></td><td>gini</td><td>37</td></tr><tr><td>max_features</td><td>0.1</td><td>4</td></tr><tr><td></td><td>0.25</td><td>5</td></tr><tr><td></td><td>0.5</td><td>7</td></tr><tr><td></td><td>0.75</td><td>15</td></tr><tr><td></td><td>log2</td><td>2</td></tr><tr><td></td><td>sqrt</td><td>2</td></tr><tr><td></td><td>null</td><td>9</td></tr><tr><td>n_estimators</td><td>10</td><td>3</td></tr><tr><td></td><td>100</td><td>17</td></tr><tr><td></td><td>50</td><td>16</td></tr><tr><td></td><td>500</td><td>6</td></tr></table> |
65c6b7736ff0e97a8f462f069466c4ed95b51613737d7b23104ef3a128f857fb.png | simple | <table><tr><td>ID</td><td>Position*</td><td>Tm
(°C)</td><td>Sequence (5′→3′)</td><td>Size (bp)</td></tr><tr><td>MYOC1</td><td>353–509</td><td>62</td><td>F: GGCTGGCTCCCC AGTATATA</td><td>174</td></tr><tr><td></td><td></td><td></td><td>R: ACAGCTGGCATCTCAGGC</td><td></td></tr><tr><td>MYOC2</td><td>491–658</td><td>62</td><td>F: ACG TTG CTG CAG CTT TGG</td><td>196</td></tr><tr><td></td><td></td><td></td><td>R: GATGACTGACATGGCCTGG</td><td></td></tr><tr><td>MYOC3</td><td>603–772</td><td>65</td><td>F: AGTGGCCGATGCCAGTATAC</td><td>189</td></tr><tr><td></td><td></td><td></td><td>R: CTGGTCCAAGGTCAATTGGT</td><td></td></tr><tr><td>MYOC4</td><td>670–864</td><td>62</td><td>F: AGGCCATGTCAGTCATCCAT</td><td>214</td></tr><tr><td></td><td></td><td></td><td>R: TCTCTGGTTTGGGTTTCCAG</td><td></td></tr><tr><td>MYOC5</td><td>778–958</td><td>60</td><td>F: TGACCTTGGACCAGGCTG</td><td>200</td></tr><tr><td></td><td></td><td></td><td>R: CCTGGCCAGATTCTCATTTT</td><td></td></tr><tr><td>MYOC6</td><td>928–1095</td><td>63</td><td>F: TGGAGGAAGAGAAGAAGCGA</td><td>187</td></tr><tr><td></td><td></td><td></td><td>R: CTGCTGAACTCAGAGTCCCC</td><td></td></tr><tr><td>MYOC7</td><td>1416–1630</td><td>62</td><td>F: AACATAGTCAATCCTTGGGCC</td><td>230</td></tr><tr><td></td><td></td><td></td><td>R: TAAAGACCATGTGGGCACA</td><td></td></tr><tr><td>MYOC8</td><td>1933–2091</td><td>60</td><td>F: TTATGGATTAAGTGGTGCTTCG</td><td>177</td></tr><tr><td></td><td></td><td></td><td>R: ATTCTCCACGTGGTCTCCTG</td><td></td></tr><tr><td>MYOC9</td><td>2069–2232</td><td>64</td><td>F: AAGCCCACCTACCCCTACAC</td><td>184</td></tr><tr><td></td><td></td><td></td><td>R: AATAGAGGCTCCCCGAGTACA</td><td></td></tr><tr><td>MYOC10</td><td>2195–2366</td><td>64</td><td>F: ATACTGCCTAGGCCACTGGA</td><td>190</td></tr><tr><td></td><td></td><td></td><td>R: CAATGTCCGTGTAGCCACC</td><td></td></tr><tr><td>MYOC11</td><td>2335–2512</td><td>63</td><td>F: TGGCTACCACGGACAGTTC</td><td>197</td></tr><tr><td></td><td></td><td></td><td>R: CATTGGCGACTGACTGCTTA</td><td></td></tr><tr><td>MYOC12</td><td>2480–2653</td><td>64</td><td>F: GAACTCGAACAAACCTGGGA</td><td>195</td></tr><tr><td></td><td></td><td></td><td>R: CATGCTGCTGTACTTATAGCGG</td><td></td></tr><tr><td>MYOC13</td><td>2624–2783</td><td>62</td><td>F: AGCAAGACCCTGACCATCC</td><td>179</td></tr><tr><td></td><td></td><td></td><td>R: AGCATCTCCTTCTGCCATTG</td><td></td></tr></table> |
f2ef6841e14161087a866cbc513725da56f73ac452ca9d04da08fa62cf83d79d.png | simple | <table><tr><td>Study</td><td>Status</td><td>Results</td><td>NCT identifier</td></tr><tr><td>Sorafenib versus placebo + FOLFOX or FOLFORI in the second-line treatment of colorectal cancer</td><td>Recruiting</td><td>Pending</td><td>NCT00889343</td></tr><tr><td>Sorafenib + capecitabine in patients with pretreated advanced CRC</td><td>Recruiting</td><td>Pending</td><td>NCT01290926</td></tr><tr><td>BAY 43-9006 plus cetuximab to treat colorectal cancer</td><td>Recruiting</td><td>Pending</td><td>NCT00326495</td></tr><tr><td>Sorafenib + FOLFORI in CRC after failure of oxaliplatin therapy</td><td>Recruiting</td><td>Pending</td><td>NCT00839111</td></tr><tr><td>Sorafenib + capecitabine in previously treated CRC</td><td>Recruiting</td><td>Pending</td><td>NCT01471353</td></tr><tr><td>Sorafenib + irinotecan in metastatic CRC and KRAS mutation</td><td>Completed</td><td>Pending</td><td>NCT00989469</td></tr><tr><td>Sorafenib, cetuximab, and irinotecan in treating patients with mCRC</td><td>Ongoing, not recruiting</td><td>Pending</td><td>NCT00134069</td></tr><tr><td>Sorafenib and bevacizumab versus single agent bevacizumab</td><td>Ongoing, not recruiting</td><td>Pending</td><td>NCT00826540</td></tr><tr><td>External-Beam radiation therapy, capecitabine, and sorafenib in treating patients with locally advanced rectal cancer</td><td>Recruiting</td><td>Pending</td><td>NCT00869570</td></tr></table> |
b400d0352a248fa88eea52d041ca65cd9a5638698f557b2fccb92abd941aab9c.png | complex | <table><tr><td>Organism</td><td>Gene targeted</td><td>Primer Sequences 5' - > 3'</td><td>Amplicon size (bp)</td><td>Reference</td></tr><tr><td rowspan="6"><i>A. phagocytophilum</i></td><td rowspan="2"><i>ankA</i></td><td>F: CTATCATCCTTGGGTAGTGGCCT</td><td rowspan="2">223</td><td rowspan="6">This study</td></tr><tr><td>R: CTTCTGGTGTTCTCGGACCTTC</td></tr><tr><td rowspan="2"><i>gltA</i></td><td>F: ATATCTACCGGAACCCCCATAGC</td><td rowspan="2">209</td></tr><tr><td>R: AAAAGCTATGACCCTAGAGCGCGT</td></tr><tr><td rowspan="2"><i>groEL</i></td><td>F: GTGATTCGCACGCTCTTAGCAGT</td><td rowspan="2">172</td></tr><tr><td>R: GCCTTCAAGTTGCTGCTGTAAA</td></tr><tr><td rowspan="5"><i>Bos taurus</i></td><td rowspan="2"><i>gapdh</i></td><td>F: TTCACACTCTCCTTCCAGGTACG</td><td rowspan="2">217</td><td rowspan="5">[30]</td></tr><tr><td>R: TCAGGGCCTTAGAGATGGAAA</td></tr><tr><td rowspan="2"><i>ywhaz</i></td><td>F: TACTCCGGACACAGGTAAGGGAC</td><td rowspan="2">212</td></tr><tr><td>R: AGAACCCAGCGGAAGAGAAG</td></tr><tr><td><i>ppia</i></td><td>F: CTGTTCTAGGTTGGATGGCAAGC</td><td>137</td></tr><tr><td></td><td></td><td>R: TTTGTCCACAGTCAGCAATGGTGA</td><td></td><td></td></tr></table> |
b244abcf5c5a119a91e07baa98e1036300dd92eb7a79ddbe8f58ab36dea3cc21.png | simple | <table><tr><td>Day</td><td>Interval</td><td>Vial</td><td>Dose (mL)</td><td>Allergen dose (mcg/mL)</td></tr><tr><td>1</td><td></td><td>2</td><td>0.1 + 0.2</td><td>0.0025 + 0.005</td></tr><tr><td>8</td><td>Weekly</td><td>2</td><td>0.4 + 0.4</td><td>0.01 + 0.01</td></tr><tr><td>15</td><td>Weekly</td><td>3</td><td>0.1 + 0.2</td><td>0.025 + 0.05</td></tr><tr><td>22</td><td>Weekly</td><td>3</td><td>0.4 + 0.4</td><td>0.1 + 0.1</td></tr><tr><td>37</td><td>Fortnightly</td><td>3</td><td>0.8</td><td>0.2</td></tr><tr><td>67</td><td>Monthly</td><td>3</td><td>0.8</td><td>0.2</td></tr><tr><td>97</td><td>Monthly</td><td>3</td><td>0.8</td><td>0.2</td></tr><tr><td>...*</td><td>Monthly</td><td>3</td><td>0.8</td><td>0.2</td></tr></table> |
5a6edc3068e8f3a5fb83a6678536e5507d5fc9610dd1ee8926e523327fa31b62.png | simple | <table><tr><td> </td><td>Control (N = 20)</td><td>Half dose (N = 20)</td><td>Early administration (N = 21)</td></tr><tr><td>Endometrial thickness</td><td> </td><td> </td><td> </td></tr><tr><td>Mean ± SD (mm)</td><td>6.7 ± 1.8</td><td>8.6 ± 1.5<sup>a</sup></td><td>9.4 ± 1.5<sup>a</sup></td></tr><tr><td>< 8 mm</td><td>17 (85.0%)</td><td>6(30.0%)</td><td>2(9.6%)</td></tr><tr><td>≥ 8 mm</td><td>3(15.0%)</td><td>14(70.0%)<sup>a</sup></td><td>19(90.4%)<sup>a</sup></td></tr><tr><td>Days until follicles maturation</td><td>12.0 ± 1.5</td><td>13.6 ± 2.7<sup>b</sup></td><td>11.6 ± 2.3</td></tr><tr><td>Number of follicles</td><td> </td><td> </td><td> </td></tr><tr><td>≥ 15 mm</td><td>1.9 ± 1.0</td><td>1.8 ± 0.9</td><td>2.3 ± 0.9</td></tr><tr><td>≥18 mm</td><td>1.3 ± 0.5</td><td>1.4 ± 0.6</td><td>1.4 ± 0.6</td></tr><tr><td>Serum progesterone (ng/ml)</td><td>22.3 ± 11.3</td><td>18.8 ± 7.3</td><td>18.8 ± 10.3</td></tr></table> |
8733316b52e6ab7e632307b4a49f1f081c6e2c21f4867c7c5c16ecdeba9b79f7.png | simple | <table><tr><td>Study report</td><td>Location</td><td>Source of cases</td><td>Number of cases</td><td>Source of comparison group without diarrhoea</td><td>Matching of comparison group</td><td>Number of children without diarrhoea</td></tr><tr><td>Bangladesh 1992a [16]</td><td>Matlab (rural)</td><td>Active household surveillance</td><td>Varied by pathogen (68 – 184)</td><td>Same community study cohort</td><td>Age and proximity of residence</td><td>Varied by pathogen (67 – 164)</td></tr><tr><td>Bangladesh 1992b [17]</td><td>Mirzapur (rural)</td><td>Active household surveillance</td><td>Varied by pathogen (53 – 153)</td><td>Same community study cohort</td><td>Age and proximity of residence</td><td>Varied by pathogen (46 – 213)</td></tr><tr><td>India 1989 [18]</td><td>New Delhi</td><td>Hospital admissions</td><td>92</td><td>Other wards with non-gastro-intestinal illnesses</td><td>Age and nutritional status</td><td>92</td></tr><tr><td>India 1992 [19]</td><td>New Delhi</td><td>Hospital admissions</td><td>81</td><td>Nutrition clinic with failure to thrive and weight for height = 90% of standard</td><td>Not matched</td><td>32</td></tr><tr><td>India 1999 [22]</td><td>Slum of New Delhi</td><td>Active household surveillance</td><td>115</td><td>Same community study cohort</td><td>Age, nutritional status and proximity of residence</td><td>115</td></tr><tr><td>Brazil 1990 [26]</td><td>Urban slum, Fortaleza</td><td>Active household surveillance</td><td>40</td><td>Same community study cohort</td><td>Not matched</td><td>38</td></tr><tr><td>Brazil 1995 [29]</td><td>Fortaleza</td><td>Hospital admissions</td><td>56</td><td>Children on other wards</td><td>By age</td><td>42</td></tr><tr><td>Brazil 2000 [4]</td><td>Shanty town, Fortaleza</td><td>Active household surveillance</td><td>88</td><td>Same community study cohort</td><td>By age and sex</td><td>443</td></tr></table> |
e2e83568d73e008e5806a3f65c8d9fd503f190065e941245fd096305c34a8091.png | complex | <table><tr><td>Dependent variable</td><td colspan="3">Acute MI</td><td colspan="3">Genotype</td><td colspan="3">Acute MI × Genotype</td></tr><tr><td> </td><td>F</td><td><i>p</i></td><td>Partial Eta squared</td><td>F</td><td><i>p</i></td><td>Partial Eta squared</td><td>F</td><td><i>p</i></td><td>Partial Eta squared</td></tr><tr><td>Serum ACE2 Levels</td><td>19.22</td><td>0.00</td><td>0.29</td><td>1.69</td><td>0.19</td><td>0.04</td><td>11.98</td><td>0.00</td><td>0.16</td></tr></table> |
254e20697b355b07c146132a37eba4b00ccb0ada16f0ad605bbb3441cd4ed86f.png | simple | <table><tr><td></td><td>Early remission n = 387</td><td>Arm 1 n = 83</td><td>Arm 2 n = 78</td><td>OOP n = 50</td></tr><tr><td>Patients with AE*, n (%)</td><td>205/387 (53 %)</td><td>53/83 (64 %)</td><td>52/78 (67 %)</td><td>27/50 (54 %)</td></tr><tr><td>Total number of AE</td><td>408</td><td>129</td><td>109</td><td>58</td></tr><tr><td>Cardiovascular</td><td>25</td><td>5</td><td>8</td><td>4</td></tr><tr><td>Pulmonary</td><td>17</td><td>5</td><td>2</td><td>2</td></tr><tr><td>Gastrointestinal</td><td>67</td><td>16</td><td>14</td><td>12</td></tr><tr><td>GI complaints</td><td>8</td><td>2</td><td>2</td><td>–</td></tr><tr><td> Nausea/emesis</td><td>23</td><td>2</td><td>4</td><td>4</td></tr><tr><td> Increased liver enzymes</td><td>15</td><td>7</td><td>3</td><td>4</td></tr><tr><td> Other</td><td>21</td><td>5</td><td>5</td><td>4</td></tr><tr><td>Neuro-psychiatric</td><td>37</td><td>5</td><td>7</td><td>3</td></tr><tr><td> Headache</td><td>14</td><td>–</td><td>4</td><td>1</td></tr><tr><td> Dizziness</td><td>7</td><td>1</td><td>–</td><td>1</td></tr><tr><td> Mood disorders</td><td>4</td><td>–</td><td>–</td><td>1</td></tr><tr><td> Other</td><td>12</td><td>4</td><td>3</td><td>–</td></tr><tr><td>Urogenital</td><td>7</td><td>3</td><td>2</td><td>3</td></tr><tr><td>Skin/mucous membranes</td><td>45</td><td>18</td><td>15</td><td>3</td></tr><tr><td> Rash</td><td>19</td><td>8</td><td>5</td><td>–</td></tr><tr><td> Hair loss/thinning</td><td>4</td><td>1</td><td>1</td><td>1</td></tr><tr><td> Sicca complaints</td><td>3</td><td>–</td><td>–</td><td>1</td></tr><tr><td> Eczema</td><td>3</td><td>1</td><td>–</td><td>–</td></tr><tr><td> Other</td><td>16</td><td>8</td><td>9</td><td>1</td></tr><tr><td>Infections</td><td>106</td><td>38</td><td>41</td><td>18</td></tr><tr><td> Upper airway tract</td><td>29</td><td>11</td><td>16</td><td>10</td></tr><tr><td> Gastrointestinal</td><td>4</td><td>1</td><td>–</td><td>2</td></tr><tr><td> Skin/mucosa</td><td>14</td><td>2</td><td>4</td><td>2</td></tr><tr><td> Pneumonia/bronchitis</td><td>9</td><td>1</td><td>1</td><td>1</td></tr><tr><td> Urinary tract</td><td>15</td><td>7</td><td>5</td><td>1</td></tr><tr><td> Influenza/unspecified fever</td><td>25</td><td>10</td><td>6</td><td>1</td></tr><tr><td> Other</td><td>10</td><td>6</td><td>9</td><td>1</td></tr><tr><td>Trauma/injury</td><td>13</td><td>5</td><td>2</td><td>3</td></tr><tr><td>Infusion reaction</td><td>3</td><td>1</td><td>–</td><td>–</td></tr><tr><td>Malaise</td><td>9</td><td>5</td><td>1</td><td>1</td></tr><tr><td>Surgical procedures without hospitalization</td><td>13</td><td>5</td><td>4</td><td>1</td></tr><tr><td>Other</td><td>65</td><td>23</td><td>12</td><td>8</td></tr></table> |
e2db6de6e6e36f1a0c76147c073e8c5a36911944670b9e3e15c875ee15363d0d.png | simple | <table><tr><td>Test</td><td>Meaning</td><td>P-value</td></tr><tr><td>1 vs. only fixed effects</td><td>QTL additive effect</td><td>6 × 10<sup>-7</sup></td></tr><tr><td>2 vs. 0</td><td>QTL additive effect conditional on infinitesimal effect</td><td>3 × 10<sup>-7</sup></td></tr><tr><td>3 vs. 0</td><td>QTL additive and dominance effects conditional on infinitesimal effect</td><td>2 × 10<sup>-6</sup></td></tr><tr><td>4 vs. 0</td><td>QTL additive effect nested within sex conditional on infinitesimal effect</td><td>3 × 10<sup>-8</sup></td></tr><tr><td>5 vs. 0</td><td>Raw association signal conditional on infinitesimal effect</td><td>5 × 10<sup>-7</sup></td></tr><tr><td>6 vs. 4</td><td>Association (SNP) signal conditional on linkage (QTL) signal</td><td>0.43</td></tr><tr><td>6 vs. 5</td><td>Linkage signal conditional on SNP signal</td><td>7 × 10<sup>-3</sup></td></tr></table> |
f7285b4ee8e1a1abf1744d02b65a3e8b5c43df4535f789887730654f19436489.png | simple | <table><tr><td>Direct costs of NSIs</td><td> </td></tr><tr><td>Testing for blood-borne viruses [6,26-30] in:</td><td> </td></tr><tr><td><i>NSI recipient – initial test</i></td><td>€38.76</td></tr><tr><td><i>NSI recipient – follow-up test</i></td><td>€58.52</td></tr><tr><td><i>Source patient (if known)</i></td><td>€43.91</td></tr><tr><td>Cost of staffing and administration per NSI [26,31]</td><td>€68.81</td></tr><tr><td>Cost of PEP for hepatitis B and HIV [19,25,32,33] per:</td><td> </td></tr><tr><td><i>NSI from a known and infected source</i></td><td>€374.61</td></tr><tr><td><i>NSI from an unknown source</i></td><td>€918.76</td></tr><tr><td>Cost of treatment of blood-borne viruses [19,25,34-38]:</td><td>€2,377.44</td></tr><tr><td><i>Hepatitis B (year in which NSI occurred and per subsequent year for three years)</i></td><td> </td></tr><tr><td><i>Hepatitis C (year in which NSI occurred only)</i></td><td>€16,127.76</td></tr><tr><td><i>HIV (year in which NSI occurred and per subsequent year)</i></td><td>€16,999.83</td></tr></table> |
6494492462df9bf683a093496110ef45757a236caecf24c9fcbc47370bd5c86b.png | simple | <table><tr><td>Number of free nicotine patches provided</td><td>Group 12-week supply</td><td>Group 24-week supply</td><td>Group 36-week supply contingent upon first 2-weeks of use</td><td>Group 46-week supply</td><td>Group 58-week supply</td></tr><tr><td>12-month quit rate*</td><td>31.0%</td><td>21.0%</td><td>15.5%</td><td>37.8%</td><td>31.1%</td></tr><tr><td>12-month intent-to-treat quit rate**</td><td>19.1%</td><td>12.9%</td><td>7.0%</td><td>23.1%</td><td>22.6%</td></tr><tr><td>Sustained quitters*</td><td>24.6%</td><td>20.3%</td><td>11.7%</td><td>27.3%</td><td>19.9%</td></tr><tr><td>Relapsed smokers*</td><td>18.9%</td><td>14.9%</td><td>16.4%</td><td>11.9%</td><td>10.2%</td></tr><tr><td>Delayed quitters*</td><td>6.4%</td><td>0.7%</td><td>3.8%</td><td>10.5%</td><td>11.3%</td></tr></table> |
899b04292498a3700beddc49f7c6f4cadffa33f2619d4e86131fceb216b0bb7f.png | simple | <table><tr><td></td><td>mNCV</td><td>CMAP</td></tr><tr><td>Patient 1</td><td>39 m/s</td><td>3.4 mV</td></tr><tr><td>Patient 2</td><td>45 m/s</td><td>4.0 mV</td></tr><tr><td>Patient 3</td><td>32 m/s</td><td>1.5 mV</td></tr><tr><td>Patient 4</td><td>32.4 m/s</td><td>5.1 mV</td></tr><tr><td>Patient 5</td><td>34.1 m/s</td><td>1.4 mV</td></tr></table> |
0dccac36c2ebe48d8286b35bcb2ee9941a8ee6be993cd61fee8a411a0f149f36.png | complex | <table><tr><td>Outcomes</td><td><i>N</i></td><td><i>p</i>-Value</td><td>B-Coefficient</td><td>95% Confidence Interval</td></tr><tr><td colspan="5">FSH</td></tr><tr><td>Tanner Stage 2 vs. Stage 1</td><td>170</td><td><0.001</td><td>1.034</td><td>(0.554; 1.514)</td></tr><tr><td>Tanner Stage 3 vs. Stage 2</td><td>110</td><td><0.001</td><td>1.416</td><td>(0.765; 2.067)</td></tr><tr><td>Tanner Stage 4 vs. Stage 3</td><td>72</td><td><0.001</td><td>1.821</td><td>(0.986; 2.657)</td></tr><tr><td>Tanner Stage 5 vs. Stage 4</td><td>41</td><td>0.287</td><td>−0.697</td><td>(−1.985; 0.590)</td></tr><tr><td colspan="5">LH</td></tr><tr><td>Tanner Stage 2 vs. Stage 1</td><td>172</td><td><0.001</td><td>0.545</td><td>(0.309; 0.781)</td></tr><tr><td>Tanner Stage 3 vs. Stage 2</td><td>111</td><td><0.001</td><td>1.163</td><td>(0.843; 1.484)</td></tr><tr><td>Tanner Stage 4 vs. Stage 3</td><td>71</td><td><0.001</td><td>0.963</td><td>(0.545; 1.380)</td></tr><tr><td>Tanner Stage 5 vs. Stage 4</td><td>40</td><td>0.805</td><td>0.080</td><td>(−0.558; 0.718)</td></tr><tr><td colspan="5">Oestradiol</td></tr><tr><td>Tanner Stage 2 vs. Stage 1</td><td>173</td><td>0.07</td><td>6.120</td><td>(−0.494; 12.733)</td></tr><tr><td>Tanner Stage 3 vs. Stage 2</td><td>112</td><td><0.001</td><td>19.993</td><td>(10.968; 29.018)</td></tr><tr><td>Tanner Stage 4 vs. Stage 3</td><td>72</td><td>0.022</td><td>13.621</td><td>(2.011; 25.230)</td></tr><tr><td>Tanner Stage 5 vs. Stage 4</td><td>41</td><td>0.006</td><td>25.320</td><td>(7.430; 43.210)</td></tr><tr><td colspan="5">Testosterone</td></tr><tr><td>Tanner Stage 2 vs. Stage 1</td><td>174</td><td>0.186</td><td>0.548</td><td>(−0.266; 1.363)</td></tr><tr><td>Tanner Stage 3 vs. Stage 2</td><td>111</td><td><0.001</td><td>5.237</td><td>(4.127; 6.347)</td></tr><tr><td>Tanner Stage 4 vs. Stage 3</td><td>72</td><td><0.001</td><td>3.347</td><td>(1.922; 4.772)</td></tr><tr><td>Tanner Stage 5 vs. Stage 4</td><td>41</td><td><0.001</td><td>4.621</td><td>(2.425; 6.818)</td></tr><tr><td colspan="5">SHBG</td></tr><tr><td>Tanner Stage 2 vs. Stage 1</td><td>172</td><td>0.008</td><td>−13.531</td><td>(−23.454; −3.608)</td></tr><tr><td>Tanner Stage 3 vs. Stage 2</td><td>111</td><td><0.001</td><td>−38.669</td><td>(−52.146; −25.191)</td></tr><tr><td>Tanner Stage 4 vs. Stage 3</td><td>71</td><td>0.009</td><td>−23.341</td><td>(−40.904; −5.778)</td></tr><tr><td>Tanner Stage 5 vs. Stage 4</td><td>40</td><td>0.999</td><td>0.023</td><td>(−26.805; 26.850)</td></tr></table> |
291eb806b20c1095b9b1c63dc0677932199d2ca1bc459dfc6fa813d3f333c265.png | complex | <table><tr><td></td><td colspan="2">OS</td><td colspan="2">PFS</td><td colspan="2">LR</td></tr><tr><td><i>Parameter</i></td><td>HR [95% CI]</td><td><i>p</i>-value</td><td>HR [95% CI]</td><td><i>p</i>-value</td><td>HR [95% CI]</td><td><i>p</i>-value</td></tr><tr><td>RT mode (IMRT vs. 3DCRT)</td><td>0.716 [0.430; 1.191]</td><td>0.198</td><td>0.830 [0.512; 1.344]</td><td>0.448</td><td>0.812 [0.356; 1.852]</td><td>0.620</td></tr><tr><td>Age (continuous)</td><td>1.006 [0.978; 1.035]</td><td>0.676</td><td>1.009 [0.981; 1.037]</td><td>0.525</td><td>0.962 [0.906; 1.022]</td><td>0.211</td></tr><tr><td>KPS (continuous)</td><td>1.004 [0.973; 1.035]</td><td>0.816</td><td>1.024 [0.992; 1.057]</td><td>0.138</td><td>0.988 [0.940; 1.039]</td><td>0.644</td></tr><tr><td>T-stage (T3/4 vs. T1/2)</td><td>1.177 [0.637; 2.178]</td><td>0.603</td><td>1.226 [0.679; 2.212]</td><td>0.499</td><td>1.170 [0.411; 3.328]</td><td>0.768</td></tr><tr><td>N-stage (N1-3 vs. N0)</td><td>1.493 [0.779; 2.863]</td><td>0.228</td><td>1.399 [0.764; 2.561]</td><td>0.277</td><td>1.218 [0.408; 3.635]</td><td>0.723</td></tr><tr><td>Grade (G3 vs. G1/2)</td><td>1.651 [0.996; 2.737]</td><td>0.052</td><td>1.518 [0.938; 2.456]</td><td>0.089</td><td>1.040 [0.455; 2.374]</td><td>0.926</td></tr><tr><td>Pretreatment Hemoglobin</td><td>0.930 [0.821; 1.054]</td><td>0.255</td><td>0.886 [0.783; 1.003]</td><td>0.057</td><td>0.975 [0.821; 1.157]</td><td>0.768</td></tr><tr><td>Location</td><td>1.002 [0.960; 1.046]</td><td>0.935</td><td>0.992 [0.952; 1.033]</td><td>0.689</td><td>1.030 [0.958; 1.107]</td><td>0.422</td></tr><tr><td>Histology (Adeno vs. SCC)</td><td>1.555 [0.786; 3.076]</td><td>0.205</td><td>1.630 [0.851; 3.125]</td><td>0.141</td><td>1.354 [0.489; 3.750]</td><td>0.560</td></tr><tr><td>RT dose (continuous)</td><td>0.946 [0.881; 1.015]</td><td>0.122</td><td>0.955 [0.893; 1.021]</td><td>0.173</td><td>0.763 [0.635; 0.916]</td><td>0.004</td></tr><tr><td>Treatment year (continuous)</td><td>1.021 [0.934; 1.116]</td><td>0.646</td><td>1.043 [0.958; 1.135]</td><td>0.329</td><td>1.041 [0.893; 1.213]</td><td>0.606</td></tr></table> |
421bd46481a17f3b10f64a5d4b58974e0d9ee9d555b88b914e3765259df78013.png | complex | <table><tr><td>Proliferation status (E2F1)</td><td colspan="3">NKI 70-gene signature prognosis</td></tr><tr><td></td><td>Good</td><td>Poor</td><td>Total</td></tr><tr><td>E2F1 ≤ p30</td><td>4/69 (5.7%)</td><td>6/21 (28.6%)</td><td>10/90 (11.1%)</td></tr><tr><td>E2F1 > p30</td><td>12/46 (26.1%)</td><td>79/159 (49.6%)</td><td>91/205 (44.4%)</td></tr><tr><td>Total</td><td>16/115 (13.9%)</td><td>85/180 (47.2%)</td><td>101/295 (34.2%)</td></tr></table> |
20e6ec3568a660c9bb15b2777d4c3fcf50a21ceffeb3fbb91f44225801289d02.png | complex | <table><tr><td>Length</td><td>Coefficient</td><td>Std. Err.</td><td>z</td><td><i>P</i> > z</td><td>[95% Conf.</td><td>Interval]</td></tr><tr><td>Days</td><td>−0.1 mm</td><td>0.1 mm</td><td>−1.16</td><td>0.25</td><td>−.4 mm</td><td>.1 mm</td></tr><tr><td>Female vs. Male</td><td>18 mm</td><td>3 mm</td><td>5.59</td><td>0.000</td><td>11 mm</td><td>24 mm</td></tr><tr><td>Right vs. Left</td><td>0 mm</td><td>3 mm</td><td>−0.15</td><td>0.88</td><td>−6 mm</td><td>5 mm</td></tr><tr><td>Displaced</td><td>−9 mm</td><td>4 mm</td><td>−2.19</td><td>0.03</td><td>−16 mm</td><td>0 mm</td></tr><tr><td>Mid vs. Lateral</td><td>1 mm</td><td>4 mm</td><td>0.38</td><td>0.70</td><td>−6 mm</td><td>8 mm</td></tr><tr><td colspan="7">Interaction displaced/time</td></tr><tr><td> Displaced over time</td><td>0 mm</td><td>0.1 mm</td><td>0.61</td><td>0.54</td><td>−0.2 mm</td><td>0.4 mm</td></tr><tr><td> Length constant</td><td>137 mm</td><td>5 mm</td><td>28.14</td><td>0.000</td><td>127 mm</td><td>147 mm</td></tr></table> |
efde415738d906ee462aa0b1733cbf6dd30861c6a66d95f09a72534f113f49b3.png | complex | <table><tr><td></td><td colspan="4">PM (mg/m<sup>3</sup>)</td><td colspan="4">Endotoxin (EU/m<sup>3</sup>)</td></tr><tr><td>Fuel/particle size</td><td><i>n</i></td><td>Range</td><td>Mean ± SD</td><td>Median</td><td>Range</td><td>Mean ± SD</td><td>Median</td><td>< LOD (<i>n</i>)</td></tr><tr><td colspan="9">Nepal, TIP</td></tr><tr><td> Wood</td><td>16</td><td>0.22–4.08</td><td>1.14 (1.12)</td><td>0.68</td><td>6–371</td><td>100 (113)</td><td>43</td><td>4a</td></tr><tr><td> Dung</td><td>15</td><td>0.91–12.8</td><td>3.78 (3.51)</td><td>2.33</td><td>133–1,002</td><td>498 (291)</td><td>365</td><td>0</td></tr><tr><td colspan="9">Malawi, Resp</td></tr><tr><td> Wood</td><td>4</td><td>1.40–9.65</td><td>4.73 (3.97)</td><td>3.94</td><td>63–520</td><td>202 (217)</td><td>113</td><td>1b</td></tr><tr><td> Maize crop residue</td><td>2</td><td>0.65–9.56</td><td>5.11 (6.30)</td><td>5.11</td><td>45–3,172</td><td>1,609 (2,211)</td><td>1,609</td><td>1c</td></tr></table> |
22e7c425bfb1ebec76973dd533703938947a547615afa0a0e764277f48745f66.png | complex | <table><tr><td></td><td colspan="3">Model 2</td></tr><tr><td></td><td>Coefficient</td><td>SE</td><td><i>P</i> > |<i>z</i>|</td></tr><tr><td>Salary</td><td>0.00006</td><td>9.79e − 06</td><td>0.000</td></tr><tr><td>Salary*health professionals</td><td>0.00001</td><td>0.00001</td><td>0.217</td></tr><tr><td>Place of work: district capital</td><td>−0.01274</td><td>0.08298</td><td>0.878</td></tr><tr><td>Place of work: district capital*health professionals</td><td>−0.46284</td><td>0.10504</td><td>0.000</td></tr><tr><td>Place of work: provincial capital</td><td>0.10538</td><td>0.06535</td><td>0.107</td></tr><tr><td>Place of work: provincial capital*health professionals</td><td>−0.30624</td><td>0.07642</td><td>0.000</td></tr><tr><td>Housing</td><td>0.53866</td><td>0.06060</td><td>0.000</td></tr><tr><td>Housing*health professionals</td><td>0.00126</td><td>0.07085</td><td>0.986</td></tr><tr><td>Access to a loan</td><td>0.38210</td><td>0.05889</td><td>0.000</td></tr><tr><td>Access to a loan*health professionals</td><td>−0.07671</td><td>0.06722</td><td>0.254</td></tr><tr><td>Formal education</td><td>0.51927</td><td>0.06637</td><td>0.000</td></tr><tr><td>Formal education*health professionals</td><td>−0.00102</td><td>0.07890</td><td>0.990</td></tr><tr><td>Skills development</td><td>0.26677</td><td>0.04949</td><td>0.000</td></tr><tr><td>Skills development*health professionals</td><td>0.01989</td><td>0.05856</td><td>0.734</td></tr><tr><td>Availability of equipment and medicine</td><td>0.25184</td><td>0.05697</td><td>0.000</td></tr><tr><td>Availability of equipment and medicine*health professionals</td><td>0.12082</td><td>0.06803</td><td>0.076</td></tr><tr><td>Private practice</td><td>0.10305</td><td>0.04295</td><td>0.016</td></tr><tr><td>Private practice*health professionals</td><td>−0.02353</td><td>0.05097</td><td>0.644</td></tr><tr><td>Const</td><td>−0.02475</td><td>0.02854</td><td>0.386</td></tr><tr><td>Number of groups</td><td>455</td><td></td><td></td></tr><tr><td>Number of observations</td><td>14 408</td><td></td><td></td></tr><tr><td>Log likelihood</td><td>−4 269.1452</td><td></td><td></td></tr><tr><td>Wald chi-square</td><td>919.02</td><td></td><td></td></tr><tr><td>Prob > chi-square</td><td>0.0000</td><td></td><td></td></tr></table> |
43b784975af49add655c3eb4d733a7e0b1d230fa659a5627d07426d3833e6a49.png | complex | <table><tr><td colspan="2">Group</td><td>Operation</td><td>Treatment</td><td colspan="2">Dose</td><td>Frequency</td><td><i>n</i></td></tr><tr><td> </td><td> </td><td> </td><td> </td><td>(μg·kg<sup>−1</sup>)</td><td>(μg·kg<sup>−1</sup> per week)</td><td> </td><td> </td></tr><tr><td>1</td><td>Sham</td><td>Sham</td><td>Vehicle</td><td>—</td><td>—</td><td>3/week</td><td>5</td></tr><tr><td>2</td><td>W3V</td><td>OVX</td><td>Vehicle</td><td>—</td><td>—</td><td>3/week</td><td>5</td></tr><tr><td>3</td><td>W3M</td><td>OVX</td><td>TPTD</td><td>6</td><td>18</td><td>3/week</td><td>5</td></tr><tr><td>4</td><td>W3H</td><td>OVX</td><td>TPTD</td><td>30</td><td>90</td><td>3/week</td><td>5</td></tr><tr><td>5</td><td>D1V</td><td>OVX</td><td>Vehicle</td><td>—</td><td>—</td><td>1/day</td><td>5</td></tr><tr><td>6</td><td>D1L</td><td>OVX</td><td>TPTD</td><td>1.2</td><td>8.4</td><td>1/day</td><td>5</td></tr><tr><td>7</td><td>D1M</td><td>OVX</td><td>TPTD</td><td>6</td><td>42</td><td>1/day</td><td>5</td></tr><tr><td>8</td><td>D1H</td><td>OVX</td><td>TPTD</td><td>30</td><td>210</td><td>1/day</td><td>5</td></tr><tr><td>9</td><td>D2V</td><td>OVX</td><td>Vehicle</td><td>—</td><td>—</td><td>2/day</td><td>5</td></tr><tr><td>10</td><td>D2L</td><td>OVX</td><td>TPTD</td><td>1.2</td><td>16.8</td><td>2/day</td><td>5</td></tr><tr><td>11</td><td>D2M</td><td>OVX</td><td>TPTD</td><td>6</td><td>84</td><td>2/day</td><td>5</td></tr><tr><td>12</td><td>D2H</td><td>OVX</td><td>TPTD</td><td>30</td><td>420</td><td>2/day</td><td>5</td></tr><tr><td>13</td><td>D3V</td><td>OVX</td><td>Vehicle</td><td>—</td><td>—</td><td>3/day</td><td>5</td></tr><tr><td>14</td><td>D3L</td><td>OVX</td><td>TPTD</td><td>1.2</td><td>25.2</td><td>3/day</td><td>5</td></tr><tr><td>15</td><td>D3M</td><td>OVX</td><td>TPTD</td><td>6</td><td>126</td><td>3/day</td><td>5</td></tr></table> |
772df1547cbf0d6e0005e0b6d11a4399c3feffe037185ca9427498049ddaceb9.png | complex | <table><tr><td>Patient details</td><td>Preoperative data</td><td>Data prior to withdrawal of epidural catheter</td></tr><tr><td>Age</td><td>Time of epidural catheterization</td><td>Time of withdrawal of epidural catheter</td></tr><tr><td>Sex</td><td>Time of blood testing</td><td>Time of blood testing</td></tr><tr><td>Epidural or intravenous analgesia</td><td>Activated partial thromboplastin time (aPTT)</td><td>Time and dosage of the last dose of low molecular weight heparin (LMWH) before withdrawal of epidural catheter</td></tr><tr><td>Reason for intravenous analgesia if applicable</td><td>Prothrombin time international normalised ratio (PT-INR)</td><td>Activated partial thromboplastin time (aPTT)</td></tr><tr><td rowspan="4">Level of epidural catheterization</td><td>Platelet count (Plc)</td><td>Prothrombin time international normalised ratio (PT-INR)</td></tr><tr><td>Blood haemoglobin level (Hb)</td><td>Platelet count (Plc)</td></tr><tr><td>Serum albumin (Alb)</td><td>Blood haemoglobin level (Hb)</td></tr><tr><td>Serum creatinine (Crea)</td><td></td></tr></table> |
ba3514353dd48cbe557ed3a8ddad3549ec5124796f4baefe81a57213634fd334.png | simple | <table><tr><td>Genotype</td><td>Frequency</td><td>Percentage</td></tr><tr><td>1 (all subtypes)</td><td>1999</td><td>7.038</td></tr><tr><td> 1(Undefined subtypes)</td><td>237</td><td>0.834</td></tr><tr><td> 1a</td><td>1369</td><td>4.82</td></tr><tr><td> 1b</td><td>336</td><td>1.183</td></tr><tr><td> 1c</td><td>57</td><td>0.2</td></tr><tr><td>2 (all subtypes)</td><td>1085</td><td>3.818</td></tr><tr><td> 2 (Undefined subtypes)</td><td>180</td><td>0.633</td></tr><tr><td> 2a</td><td>821</td><td>2.89</td></tr><tr><td> 2b</td><td>78</td><td>0.274</td></tr><tr><td> 2c</td><td>6</td><td>0.021</td></tr><tr><td>3 (all subtypes)</td><td>22429</td><td>78.964</td></tr><tr><td> 3 (Undefined subtypes)</td><td>3104</td><td>10.92</td></tr><tr><td> 3a</td><td>16475</td><td>58.01</td></tr><tr><td> 3b</td><td>2772</td><td>9.76</td></tr><tr><td> 3c</td><td>75</td><td>0.264</td></tr><tr><td> 3k</td><td>3</td><td>0.01</td></tr><tr><td>4 (all subtypes)</td><td>453</td><td>1.594</td></tr><tr><td> 4 (Undefined subtypes)</td><td>264</td><td>0.929</td></tr><tr><td> 4a</td><td>173</td><td>0.609</td></tr><tr><td> 4b</td><td>16</td><td>0.056</td></tr><tr><td>5 (all subtypes)</td><td>29</td><td>0.101</td></tr><tr><td> 5 (Undefined subtypes)</td><td>5</td><td>0.017</td></tr><tr><td> 5a</td><td>24</td><td>0.084</td></tr><tr><td>6(all subtypes)</td><td>37</td><td>0.13</td></tr><tr><td> 6 (Undefined subtypes)</td><td>25</td><td>0.088</td></tr><tr><td> 6</td><td>12</td><td>0.042</td></tr><tr><td>Undefined subtypes</td><td>939</td><td>3.306</td></tr><tr><td>Mixed</td><td>1429</td><td>5.031</td></tr><tr><td>Total</td><td>28400</td><td>100</td></tr></table> |
b3badbdc7d6abcc2fcc3e84f55e2e73c97ee66c540900826a08f09cc05427e02.png | simple | <table><tr><td>Target population</td><td>Approach</td><td>Number conducted</td><td>Target population reached</td></tr><tr><td>Male and female adolescents</td><td>FGD</td><td>6</td><td>48</td></tr><tr><td>Women with children under 5 years</td><td>FGD</td><td>6</td><td>32</td></tr><tr><td>Men whose children have or have not been involved in any study conducted by KHRC</td><td>FGD</td><td>6</td><td>37</td></tr><tr><td>Women 45 years+</td><td>FGD</td><td>6</td><td>43</td></tr><tr><td>Traditional leaders</td><td>IDI</td><td>2</td><td>2</td></tr><tr><td>Assembly men and women and government appointees.</td><td>IDI</td><td>12</td><td>12</td></tr><tr><td>Head of district commission for human rights and administrative justice.</td><td>IDI</td><td>1</td><td>1</td></tr><tr><td>District Information officer.</td><td>IDI</td><td>1</td><td>1</td></tr><tr><td>Church leaders</td><td>IDI</td><td>2</td><td>2</td></tr><tr><td>Ghana Private Road Transport Union (GPRTU ) Official</td><td>IDI</td><td>1</td><td>1</td></tr><tr><td>Health professionals</td><td>IDI</td><td>3</td><td>3</td></tr><tr><td>Traditional healer</td><td>IDI</td><td>1</td><td>1</td></tr><tr><td>Director of Agriculture</td><td>IDI</td><td>1</td><td>1</td></tr><tr><td>Unit committee members.</td><td>IDI</td><td>1</td><td>1</td></tr><tr><td>Chemical drug sellers</td><td>IDI</td><td>2</td><td>2</td></tr><tr><td>Ghana Police personnel</td><td>IDI</td><td>2</td><td>2</td></tr><tr><td>Community members</td><td>Radio discussions</td><td>7</td><td>~52,000</td></tr><tr><td>Community members</td><td>Community durbars</td><td>33</td><td>~86,700</td></tr><tr><td>Assembly members, the media, health professionals and other government organizations</td><td>Workshops</td><td>5</td><td>145</td></tr></table> |
a625976138a844af473c995e122abe41bdc22b4df2d323ed92a5118748916022.png | simple | <table><tr><td>Landmarks</td><td>Lee et al. [13] Mean (mm) ± SD</td><td>Lee [16] Mean (mm) ± SD</td></tr><tr><td>Height of maxillary sinus roof</td><td>33.45 ± 2.83</td><td>33.83 ± 3.40</td></tr><tr><td>Maxillary sinus roof to posterior ethmoid roof</td><td>14.08 ± 3.03</td><td>Not measured</td></tr><tr><td>Maxillary sinus roof to sphenoid ostium</td><td>2.76 ± 2.80</td><td>1.79 ± 3.09</td></tr><tr><td>Maxillary sinus roof to sphenoid roof</td><td>12.18 ± 3.20</td><td>12.02 ± 2.93</td></tr><tr><td>Maxillary sinus roof to sphenoid floor</td><td>5.94 ± 2.94</td><td>6.18 ± 2.88</td></tr></table> |
818ca96ef6425e108693295fe7aed54999b0b5902466d0c697880ba97f2a391b.png | complex | <table><tr><td></td><td>Automatic selection 450 K</td><td>Automatic selection EPIC</td><td>IDOL EPIC</td><td><i>P</i><sup>a</sup></td></tr><tr><td>Probes</td><td>(<i>n</i> = 600)</td><td>(<i>n</i> = 600)</td><td>(<i>n</i> = 450)</td><td></td></tr><tr><td></td><td>N(%)</td><td>N(%)</td><td>N(%)</td><td></td></tr><tr><td>CpG present on 450 K array</td><td>600 (100)</td><td>203 (34)</td><td>140 (31)</td><td>7.50E-29</td></tr><tr><td>Enhancers (Phantom5)</td><td>53 (9)</td><td>108 (18)</td><td>70 (16)</td><td>3.13E-69</td></tr><tr><td>DNase hypersensitive sites</td><td>452 (75)</td><td>467 (78)</td><td>328 (73)</td><td>6.66E-147</td></tr><tr><td colspan="5">Genomic context</td></tr><tr><td> CpG island</td><td>47 (8)</td><td>24 (4)</td><td>10 (2)</td><td>4.35E-62</td></tr><tr><td> Shores</td><td>116 (19)</td><td>55 (9)</td><td>63 (14)</td><td rowspan="3"></td></tr><tr><td> Shelves</td><td>95 (16)</td><td>41 (7)</td><td>35 (8)</td></tr><tr><td> Open sea</td><td>342 (57)</td><td>480 (80)</td><td>342 (76)</td></tr><tr><td colspan="5">Functional context</td></tr><tr><td> TSS1500</td><td>73 (12)</td><td>44 (7)</td><td>38 (8)</td><td>2.10E-102</td></tr><tr><td> TSS200</td><td>46 (8)</td><td>23 (4)</td><td>11 (2)</td><td rowspan="6"></td></tr><tr><td> 5′ UTR</td><td>76 (13)</td><td>69 (12)</td><td>46 (10)</td></tr><tr><td> First exon</td><td>20 (3)</td><td>16 (3)</td><td>7 (2)</td></tr><tr><td> Body</td><td>241 (40)</td><td>283 (47)</td><td>210 (47)</td></tr><tr><td> 3′ UTR</td><td>29 (5)</td><td>11 (2)</td><td>9 (2)</td></tr><tr><td> Intergenic</td><td>115 (19)</td><td>152 (25)</td><td>128 (28)</td></tr></table> |
b9ae90f0c226646e3c3fa90b2627b6d24227d5c714cf6b2ea14517ee5553c30b.png | simple | <table><tr><td>Variable</td><td>Coefficient</td><td><i>P</i></td></tr><tr><td>Prior history of radiation</td><td>−1.350</td><td>.012</td></tr><tr><td>Volume per injection, mL</td><td>2.060</td><td>.094</td></tr></table> |
135caaff6edcfb710f0b21d24821f1399076302f648968dbbfd992aad1bb0d00.png | simple | <table><tr><td>Dosimetry Parameter</td><td>Planned</td><td>St Dev</td><td>Implanted</td><td>St Dev</td></tr><tr><td>D90 (Gy)</td><td>175.5</td><td>9.6</td><td>177.7</td><td>10.5</td></tr><tr><td>V100 (%)</td><td>97.9</td><td>1.6</td><td>97.9</td><td>1.5</td></tr><tr><td>V150 (%)</td><td>64.1</td><td>7.3</td><td>66.5</td><td>7.9</td></tr><tr><td>V200 (%)</td><td>21.6</td><td>5.9</td><td>26.1</td><td>7.3</td></tr></table> |
518f480df1fa433463a03a11f05984611f8267bdc1202d83e50e1e1e2cec94be.png | simple | <table><tr><td>Drug</td><td>Disease</td><td>NCT number</td><td>Phase</td></tr><tr><td>5-Azacitidine</td><td>Beta thalassemia</td><td>NCT00005934</td><td>Phase 2</td></tr><tr><td>5-Azacytidine + Na phenylbutyrate</td><td>Thalassemia major</td><td>NCT00007072</td><td>Phase 2</td></tr><tr><td>Resveratrol</td><td>Cardiovascular diseases</td><td>NCT01449110</td><td>Phase 2</td></tr><tr><td>Resveratrol</td><td>Trauma</td><td>NCT01321151</td><td>Phase 1</td></tr><tr><td>Resveratrol</td><td>Metabolic syndrome, obesity</td><td>NCT01150955</td><td>Phase 1</td></tr><tr><td>Curcumin</td><td>Irritable bowel syndrome</td><td>NCT00779493</td><td>Phase 4</td></tr><tr><td>Curcumin</td><td>Alzheimer disease</td><td>NCT00164749</td><td>Phase 2</td></tr><tr><td>Curcumin</td><td>Psoriasis</td><td>NCT00235625</td><td>Phase 2</td></tr></table> |
e486eb73ab3c9f1af8073c98137d56704984cc8f1bb4ab41727b3d1ba7e3c9c6.png | simple | <table><tr><td>N</td><td>Subfamily</td><td>Unit (bp)</td><td>Arrays</td><td>GC%</td><td>Length (bp)</td><td>Var%</td><td>HOR</td><td>ChrUn</td><td>WGS Chr</td></tr><tr><td>1</td><td>TR-24B-MM</td><td>24</td><td>3</td><td>34.4</td><td>7636</td><td>28</td><td>+</td><td>2</td><td>11</td></tr><tr><td>2</td><td>TR-24A-MM</td><td>24</td><td>2</td><td>45.6</td><td>3540</td><td>22</td><td>+</td><td>2</td><td>Un</td></tr><tr><td>3</td><td>TR-13A-MM</td><td>13</td><td>1</td><td>56.0</td><td>4477</td><td>15</td><td>+</td><td>0</td><td>6</td></tr><tr><td>4</td><td>TR-27B-MM</td><td>27</td><td>1</td><td>63.5</td><td>3452</td><td>36</td><td>+</td><td>1</td><td>Un</td></tr><tr><td>5</td><td>TR-28A-MM</td><td>28</td><td>1</td><td>41.2</td><td>3195</td><td>23</td><td>+</td><td>1</td><td>Un</td></tr><tr><td>6</td><td>TR-36A-MM</td><td>36</td><td>1</td><td>64.0</td><td>3003</td><td>8</td><td>+</td><td>0</td><td>19</td></tr><tr><td>7</td><td>TR-102A-MM</td><td>102</td><td>1</td><td>45.7</td><td>3698</td><td>31</td><td>-</td><td>0</td><td>X</td></tr><tr><td>8</td><td>TR-624A-MM</td><td>624</td><td>1</td><td>43.3</td><td>3297</td><td>2</td><td>-</td><td>0</td><td>Un</td></tr></table> |
a47eee67d8dfcee4a7e5fb12f4d8c23dc632a4cd087ace5a623ff17bc1219e2b.png | complex | <table><tr><td></td><td colspan="8">Assessment Period</td></tr><tr><td>Measure</td><td>E1</td><td>E2</td><td>2 weeks</td><td>6 weeks</td><td>13-weeks</td><td>6 month</td><td>1 year</td><td>2 years</td></tr><tr><td>Height, weight</td><td colspan="6">Monthly</td><td colspan="2">Every 3 months</td></tr><tr><td>DXA</td><td></td><td>X</td><td></td><td></td><td>X</td><td>X</td><td>X</td><td>X</td></tr><tr><td>Waist Circumference</td><td colspan="6">Monthly</td><td colspan="2">Every 3 months</td></tr><tr><td>Blood Pressure</td><td></td><td></td><td></td><td>X</td><td>X</td><td>X</td><td>X</td><td>X</td></tr><tr><td>Aerobic fitness</td><td></td><td>X</td><td></td><td></td><td>X</td><td>X</td><td>X</td><td>X</td></tr><tr><td>Strength fitness</td><td></td><td>X</td><td></td><td></td><td>X</td><td>X</td><td>X</td><td>X</td></tr><tr><td>ActicalTM</td><td></td><td>X</td><td></td><td></td><td>X</td><td>X</td><td>X</td><td>X</td></tr><tr><td>7-day PAR</td><td></td><td>X</td><td></td><td></td><td>X</td><td>X</td><td>X</td><td>X</td></tr><tr><td>Ultrasound</td><td></td><td>X</td><td></td><td></td><td>X</td><td>X</td><td>X</td><td>X</td></tr><tr><td>EKG</td><td></td><td>X</td><td></td><td></td><td>X</td><td>X</td><td>X</td><td>X</td></tr><tr><td>PAT</td><td>X</td><td></td><td></td><td></td><td></td><td>X</td><td>X</td><td>X</td></tr><tr><td>Blood work</td><td>X</td><td></td><td></td><td></td><td></td><td>X</td><td>X</td><td>X</td></tr><tr><td>3-day food records</td><td></td><td></td><td></td><td>X</td><td>X</td><td>X</td><td>X</td><td>X</td></tr><tr><td>Quality of Life</td><td></td><td>X</td><td></td><td></td><td>X</td><td>X</td><td>X</td><td>X</td></tr><tr><td>Social Support</td><td></td><td>X</td><td></td><td></td><td>X</td><td>X</td><td>X</td><td>X</td></tr><tr><td>Outcome Expectations</td><td></td><td>X</td><td></td><td>X</td><td>X</td><td>X</td><td>X</td><td>X</td></tr><tr><td>Satisfaction</td><td></td><td>X</td><td></td><td>X</td><td>X</td><td>X</td><td>X</td><td>X</td></tr><tr><td>Enjoyment</td><td></td><td>X</td><td></td><td>X</td><td>X</td><td>X</td><td>X</td><td>X</td></tr><tr><td>Self-efficacy</td><td></td><td></td><td>X</td><td>X</td><td>X</td><td>X</td><td>X</td><td>X</td></tr><tr><td>Group Cohesion</td><td></td><td></td><td>X</td><td></td><td>X</td><td></td><td></td><td></td></tr><tr><td>Collaboration</td><td></td><td></td><td>X</td><td></td><td>X</td><td></td><td></td><td></td></tr><tr><td>Intentions</td><td></td><td></td><td>X</td><td>X</td><td>X</td><td>X</td><td>X</td><td>X</td></tr></table> |
b29beb176c27bfaace272f2047c8f99d7a036e27cc2095a9882d3dc15a14bad0.png | simple | <table><tr><td>Patient</td><td>Age/years</td><td>LH (mIU/ml)</td><td>FSH (mIU/ml)</td><td>Prolactin (ng/ml)</td><td>Estradiol (pg/ml)</td><td>Progesterone (ng/ml)</td><td>Testosterone (ng/ml)</td><td>Follicle numbers</td><td>Clinical information</td></tr><tr><td>F1‐II1</td><td>34</td><td>6.58</td><td>17.49↑</td><td>19.55</td><td>40</td><td>0.15</td><td>0.85</td><td>Left: 5, Right: 10</td><td>BPES; Menarche 16 years; irregular cycles</td></tr><tr><td>F2‐II1</td><td>30</td><td>10.33</td><td>17.84↑</td><td>7.16</td><td>42</td><td>0.2</td><td>0.59</td><td>Left: 2, Right: 3</td><td>BPES; Menarche 15 years; irregular cycles</td></tr></table> |
49ea9ef4365ff3202ec00f5edc9816e3d75bcca84693244cf34344152dae4e49.png | complex | <table><tr><td>Survival</td><td colspan="2"><i>MYC</i> CNA<sup>+</sup> and <i>MYC</i>-R<sup>+</sup></td><td colspan="2"><i>MYC</i>-R<sup>+</sup> alone</td><td colspan="2"><i>MYC</i> CNA<sup>+</sup> alone</td></tr><tr><td></td><td>χ<sup>2</sup></td><td><i>P</i> value</td><td>χ<sup>2</sup></td><td><i>P</i> value</td><td>χ<sup>2</sup></td><td><i>P</i> value</td></tr><tr><td>Overall survival</td><td></td><td></td><td></td><td></td><td></td><td></td></tr><tr><td><i>MYC</i> CNA<sup>+</sup> and <i>MYC</i>-R<sup>+</sup></td><td></td><td></td><td>2.819</td><td>0.093</td><td>0.066</td><td>0.797</td></tr><tr><td><i>MYC</i>-R<sup>+</sup> alone</td><td>2.819</td><td>0.093</td><td></td><td></td><td>0.339</td><td>0.560</td></tr><tr><td><i>MYC</i> CNA<sup>+</sup> alone</td><td>0.066</td><td>0.797</td><td>0.339</td><td>0.560</td><td></td><td></td></tr><tr><td>Progression-free survival</td><td></td><td></td><td></td><td></td><td></td><td></td></tr><tr><td><i>MYC</i> CNA<sup>+</sup> and <i>MYC</i>-R<sup>+</sup></td><td></td><td></td><td>3.481</td><td>0.062</td><td>4.499</td><td>0.034</td></tr><tr><td><i>MYC</i>-R<sup>+</sup> alone</td><td>3.481</td><td>0.062</td><td></td><td></td><td>3.400</td><td>0.054</td></tr><tr><td><i>MYC</i> CNA<sup>+</sup> alone</td><td>4.499</td><td>0.034</td><td>3.400</td><td>0.054</td><td></td><td></td></tr></table> |
42f87a9ddcb4fa3508a186fc296d600a4c98d199a23ce4adc1f112690aa5cf5c.png | simple | <table><tr><td> </td><td>Before sling</td><td>After sling</td></tr><tr><td>PVDF</td><td>15.4 (±4.3)</td><td>5.6 (±5.9)</td></tr><tr><td>PP</td><td>15.3 (±3.4)</td><td>6.2 (±6.6)</td></tr></table> |
23422e6a208f0e38e0361f3e3dbe5e426ec16624af3c7a98b020fc747246c64a.png | complex | <table><tr><td rowspan="2">Characteristics</td><td rowspan="2">Cases</td><td colspan="2">CD40 mutant expression</td><td rowspan="2"><i>χ</i><sup><i>2</i></sup></td><td rowspan="2"><i>P</i></td></tr><tr><td>Positive</td><td>Negative</td></tr><tr><td>Sex</td><td> </td><td> </td><td> </td><td> </td><td> </td></tr><tr><td>Male</td><td>58</td><td>33</td><td>25</td><td rowspan="2">0.286</td><td rowspan="2">0.593</td></tr><tr><td>Female</td><td>20</td><td>10</td><td>10</td></tr><tr><td>Age (years)</td><td> </td><td> </td><td> </td><td> </td><td> </td></tr><tr><td>≥60</td><td>48</td><td>36</td><td>12</td><td rowspan="2">2.849</td><td rowspan="2">0.091</td></tr><tr><td><60</td><td>30</td><td>17</td><td>13</td></tr><tr><td>Tumor size (cm)</td><td> </td><td> </td><td> </td><td> </td><td> </td></tr><tr><td>≥5</td><td>37</td><td>20</td><td>17</td><td rowspan="2">0.033</td><td rowspan="2">0.856</td></tr><tr><td><5</td><td>41</td><td>23</td><td>18</td></tr><tr><td>Differentiation</td><td> </td><td> </td><td> </td><td> </td><td> </td></tr><tr><td>Well/moderate</td><td>43</td><td>20</td><td>23</td><td rowspan="2">2.074</td><td rowspan="2">0.15</td></tr><tr><td>Poor</td><td>35</td><td>22</td><td>13</td></tr><tr><td>Depth of tumor invasion</td><td> </td><td> </td><td> </td><td> </td><td> </td></tr><tr><td>Not to deep muscle layer</td><td>10</td><td>1</td><td>9</td><td rowspan="2">9.444</td><td rowspan="2">0.002<sup>a</sup></td></tr><tr><td>Deep muscle layer</td><td>68</td><td>42</td><td>26</td></tr><tr><td>Lymph nodes metastasis</td><td> </td><td> </td><td> </td><td> </td><td> </td></tr><tr><td>Yes</td><td>60</td><td>39</td><td>21</td><td rowspan="2">7.802</td><td rowspan="2">0.005<sup>a</sup></td></tr><tr><td>No</td><td>18</td><td>5</td><td>13</td></tr><tr><td>TNM stage</td><td> </td><td> </td><td> </td><td> </td><td> </td></tr><tr><td>I and II</td><td>17</td><td>4</td><td>13</td><td rowspan="2">8.774</td><td rowspan="2">0.003<sup>a</sup></td></tr><tr><td>III and IV</td><td>61</td><td>39</td><td>22</td></tr></table> |
ad6a355c44a572a4d1b731ce59c01a74f1dfb95b381c65a89028edcc2c3931b3.png | simple | <table><tr><td>Variable</td><td>AHRR <36(n=181)</td><td>AHRR 36–46(n=202)</td><td>AHRR 47–58(n=197)</td><td>AHRR ≥59(n=211)</td><td>p Value(across all groups)</td></tr><tr><td>Age (years)</td><td>71.1 (0.8)</td><td>69.1 (0.8)</td><td>67.8 (0.9)</td><td>63.9 (0.9)</td><td><0.001</td></tr><tr><td>Resting heart rate (bpm)</td><td>70 (2)</td><td>71 (1)</td><td>73 (1)</td><td>80 (1)</td><td><0.001</td></tr><tr><td>Systolic blood pressure (mm Hg)</td><td>121 (2)</td><td>121 (2)</td><td>121 (2)</td><td>123 (2)</td><td>0.71</td></tr><tr><td>QRS interval (ms)</td><td>126 (2)</td><td>125 (2)</td><td>122 (2)</td><td>116 (2)</td><td>0.01</td></tr><tr><td>Haemoglobin (g/dL)</td><td>129 (1)</td><td>136 (1)</td><td>136 (1)</td><td>142 (1)</td><td><0.001</td></tr><tr><td>Sodium (mmol/L)</td><td>139 (1)</td><td>139 (1)</td><td>140 (1)</td><td>140 (1)</td><td>0.12</td></tr><tr><td>eGFR (mL/Kg/1.73 m<sup>2</sup>)</td><td>49 (1)</td><td>54 (1)</td><td>56 (1)</td><td>61 (1)</td><td><0.001</td></tr><tr><td>LV ejection fraction (%)</td><td>33 (1)</td><td>32 (1)</td><td>32 (1)</td><td>31 (1)</td><td>0.58</td></tr><tr><td>Minimum 24 h heart rate (bpm)</td><td>59 (1)</td><td>58 (1)</td><td>56 (1)</td><td>57 (1)</td><td>0.37</td></tr><tr><td>Maximum 24 h heart rate (bpm)</td><td>86 (1)</td><td>98 (1)</td><td>108 (1)</td><td>133 (1)</td><td><0.001</td></tr><tr><td>Ambulatory heart rate range (bpm)</td><td>28 (1)</td><td>41 (1)</td><td>52 (1)</td><td>76 (1)</td><td><0.001</td></tr><tr><td>Male sex (% (n))</td><td>73.5 (133)</td><td>73.8 (149)</td><td>74.1 (146)</td><td>73.5 (155)</td><td>0.99</td></tr><tr><td>Ischaemic aetiology (% (n))</td><td>79 (143)</td><td>69.3 (140)</td><td>66 (130)</td><td>42.2 (89)</td><td><0.001</td></tr><tr><td>NYHA class</td><td></td><td></td><td></td><td></td><td>0.12</td></tr><tr><td> I</td><td>14.4 (26)</td><td>17.9 (36)</td><td>25.4 (50)</td><td>24.3 (51)</td><td></td></tr><tr><td> II</td><td>48.1 (87)</td><td>46.3 (93)</td><td>39.6 (78)</td><td>48.1 (101)</td><td></td></tr><tr><td> III</td><td>35.4 (64)</td><td>33.3 (67)</td><td>33.5 (66)</td><td>26.7 (56)</td><td></td></tr><tr><td> IV</td><td>2.2 (4)</td><td>2.5 (5)</td><td>1.5 (3)</td><td>1 (2)</td><td></td></tr><tr><td>Any device therapy (% (n))</td><td>36.5 (66)</td><td>32.2 (65)</td><td>24.9 (49)</td><td>20.4 (43)</td><td>0.002</td></tr><tr><td>Cardiac resynchronisation (% (n))</td><td>28.7 (52)</td><td>28.7 (58)</td><td>23.4 (46)</td><td>19 (40)</td><td>0.06</td></tr><tr><td>Implantable defibrillator (% (n))</td><td>18.2 (33)</td><td>13.4 (27)</td><td>8.6 (17)</td><td>9 (19)</td><td>0.01</td></tr><tr><td>Any atrial fibrillation or flutter (% (n))</td><td>22 (39)</td><td>23.9 (48)</td><td>30.4 (58)</td><td>48.8 (100)</td><td><0.001</td></tr><tr><td>Non-sustained VT (% (n))</td><td>36.9 (65)</td><td>35.8 (72)</td><td>37.6 (71)</td><td>47.1 (96)</td><td>0.08</td></tr><tr><td>Diabetes (% (n))</td><td>40.9 (74)</td><td>28.7 (58)</td><td>20.8 (41)</td><td>14.7 (31)</td><td><0.001</td></tr><tr><td>β-blocker use (% (n))</td><td>82.3 (149)</td><td>81 (162)</td><td>77.2 (152)</td><td>76.6 (160)</td><td>0.42</td></tr><tr><td>β-blocker dose (mg bisoprolol/day)</td><td>4.0 (0.3)</td><td>3.4 (0.2)</td><td>3.6 (0.2)</td><td>3.1 (0.2)</td><td>0.088</td></tr><tr><td>ACEi/ARB use (% (n))</td><td>86.7 (157)</td><td>87 (174)</td><td>91.4 (180)</td><td>87.6 (183)</td><td>0.45</td></tr><tr><td>MRA use (% (n))</td><td>45.9 (83)</td><td>43.5 (87)</td><td>41.1 (81)</td><td>32.1 (67)</td><td>0.03</td></tr><tr><td>Furosemide dose (mg/day)</td><td>66 (4)</td><td>56 (4)</td><td>52 (4)</td><td>40 (3)</td><td><0.001</td></tr></table> |
fcf3063253361aa834f0eef4b8c99e254ef59b91fd8d70cd53bf3de52af81d92.png | complex | <table><tr><td>Age (Weeks)</td><td>Sex</td><td>CF1-CD</td><td>CF1-HCD</td><td>DF1-CD</td><td>DF1-HCD</td></tr><tr><td colspan="6">Hepatic TGs content (mg/g tissue)</td></tr><tr><td rowspan="2">5</td><td>Male</td><td>76.4 ± 7</td><td>78 ± 8</td><td>77 ± 6</td><td>79 ± 6</td></tr><tr><td>Female</td><td>74 ± 6</td><td>76 ± 5</td><td>75 ± 5</td><td>76 ± 5</td></tr><tr><td rowspan="2">10</td><td>Male</td><td>81 ± 8</td><td>85 ± 8</td><td>87 ± 7</td><td>91 ± 8*</td></tr><tr><td>Female</td><td>78 ± 5</td><td>80 ± 6</td><td>81 ± 5***</td><td>85 ± 7*</td></tr><tr><td rowspan="2">15</td><td>Male</td><td>84 ± 7</td><td>92 ± 9*</td><td>96 ± 8*</td><td>105 ± 9*,**</td></tr><tr><td>Female</td><td>81 ± 5</td><td>84 ± 7***</td><td>86 ± 7***</td><td>92 ± 7*,**,***</td></tr><tr><td rowspan="2">20</td><td>Male</td><td>86 ± 8</td><td>94 ± 8*</td><td>98 ± 6*</td><td>109 ± 9*,**</td></tr><tr><td>Female</td><td>83 ± 6</td><td>88 ± 6</td><td>92 ± 7*</td><td>99 ± 10*,**,***</td></tr><tr><td rowspan="2">25</td><td>Male</td><td>94 ± 9</td><td>99 ± 9</td><td>103 ± 9*</td><td>111 ± 10*,**</td></tr><tr><td>Female</td><td>87 ± 6</td><td>94 ± 7</td><td>98 ± 6*</td><td>104 ± 8*,**</td></tr><tr><td rowspan="2">30</td><td>Male</td><td>98 ± 9</td><td>104 ± 10</td><td>108 ± 9*</td><td>116 ± 10*,**</td></tr><tr><td>Female</td><td>92 ± 7</td><td>96 ± 8</td><td>102 ± 8*</td><td>110 ± 9*,**</td></tr><tr><td colspan="6">Muscular TGs content (mg/g tissue)</td></tr><tr><td rowspan="2">5</td><td>Male</td><td>1.52 ± 0.12</td><td>1.53 ± 0.1</td><td>1.6 ± 0.11</td><td>1.65 ± 0.13*,**</td></tr><tr><td>Female</td><td>1.44 ± 0.11</td><td>1.5 ± 0.11</td><td>1.48 ± 0.12***</td><td>1.51 ± 0.12***</td></tr><tr><td rowspan="2">10</td><td>Male</td><td>1.75 ± 0.1</td><td>1.9 ± 0.14*</td><td>1.84 ± 0.14</td><td>2.25 ± 0.17*,**</td></tr><tr><td>Female</td><td>1.63 ± 0.13***</td><td>1.82 ± 0.13*</td><td>1.71 ± 0.13***</td><td>1.88 ± 0.12*,***</td></tr><tr><td rowspan="2">15</td><td>Male</td><td>1.82 ± 0.12</td><td>2.1 ± 0.12*</td><td>2.05 ± 0.16*</td><td>2.74 ± 0.21*,**</td></tr><tr><td>Female</td><td>1.71 ± 0.1***</td><td>1.85 ± 0.12*,***</td><td>1.89 ± 0.17*,***</td><td>2.2 ± 0.16*,**,***</td></tr><tr><td rowspan="2">20</td><td>Male</td><td>2 ± 0.11</td><td>2.15 ± 0.14*</td><td>2.20 ± 0.15*</td><td>2.81 ± 0.17*,**</td></tr><tr><td>Female</td><td>1.86 ± 0.14***</td><td>1.94 ± 0.13***</td><td>2.04 ± 0.17*,***</td><td>2.32 ± 0.21*,**,***</td></tr><tr><td rowspan="2">25</td><td>Male</td><td>2.1 ± 0.12</td><td>2.2 ± 0.15</td><td>2.48 ± 0.2*,**</td><td>2.96 ± 0.23*,**</td></tr><tr><td>Female</td><td>1.94 ± 0.13***</td><td>2.1 ± 0.12*</td><td>2.2 ± 0.16<sup>*,***</sup></td><td>2.46 ± 0.21*,**,***</td></tr><tr><td rowspan="2">30</td><td>Male</td><td>1.9 ± 0.1</td><td>2.2 ± 0.15*</td><td>2.7 ± 0.15*,**</td><td>3 ± 0.26*,**</td></tr><tr><td>Female</td><td>1.85 ± 0.12</td><td>1.98 ± 0.11***</td><td>2.55 ± 0.18*,**</td><td>2.78 ± 0.19*,**,***</td></tr></table> |
d447dd12569d7f1a5baafeaa72639586211b8424a9d6d2602ceed85c961f3efe.png | simple | <table><tr><td></td><td>H<sub>2</sub>O</td><td>M9 medium</td><td>LB medium</td><td>10 fold diluted LB medium</td></tr><tr><td>Linear range of adenosine concentrations (mM)</td><td>0.065–10</td><td>0.054–10</td><td>3.2–10</td><td>0.098–10</td></tr><tr><td>Detection limit (mM)</td><td>0.065</td><td>0.054</td><td>3.2</td><td>0.098</td></tr><tr><td>Z′(calculated with 1 and 10 mM)</td><td>0.881</td><td>0.911</td><td>0.652</td><td>0.902</td></tr><tr><td>Concentration of adenosine/mM</td><td>S/B(H<sub>2</sub>O)</td><td>S/B(M9 medium)</td><td>S/B(LB medium)</td><td>S/B(10-fold diluted LB medium)</td></tr><tr><td>0.01</td><td>1.08</td><td>2.76</td><td></td><td>1.03</td></tr><tr><td>0.025</td><td>1.19</td><td>2.90</td><td></td><td>1.03</td></tr><tr><td>0.05</td><td>1.38</td><td>3.08</td><td></td><td>1.07</td></tr><tr><td>0.075</td><td>1.51</td><td>3.29</td><td></td><td>1.07</td></tr><tr><td>0.1</td><td>1.66</td><td>3.56</td><td></td><td>1.08</td></tr><tr><td>0.25</td><td>2.66</td><td>4.80</td><td></td><td>1.23</td></tr><tr><td>0.5</td><td>4.31</td><td>6.88</td><td>1.44</td><td>1.44</td></tr><tr><td>0.75</td><td>6.14</td><td>9.27</td><td>1.46</td><td>1.66</td></tr><tr><td>1</td><td>7.79</td><td>11.65</td><td>1.50</td><td>1.89</td></tr><tr><td>2</td><td>14.37</td><td>16.97</td><td>1.61</td><td>2.82</td></tr><tr><td>3</td><td>19.59</td><td>24.69</td><td>1.73</td><td>3.83</td></tr><tr><td>4</td><td>24.80</td><td>32.62</td><td>1.84</td><td>4.64</td></tr><tr><td>5</td><td>31.15</td><td>38.84</td><td>1.95</td><td>5.27</td></tr><tr><td>6</td><td>36.31</td><td>47.54</td><td>2.01</td><td>6.29</td></tr><tr><td>7</td><td>42.47</td><td>54.51</td><td>2.11</td><td>7.02</td></tr><tr><td>8</td><td>47.33</td><td>62.92</td><td>2.21</td><td>7.79</td></tr><tr><td>9</td><td>52.85</td><td>65.68</td><td>2.30</td><td>8.97</td></tr><tr><td>10</td><td>58.54</td><td>71.32</td><td>2.35</td><td>9.51</td></tr></table> |
f21e8c9dfa50b79992395828391b6d2a9bf9d678e05064319e783724c5ae55f9.png | simple | <table><tr><td>Lottery A</td><td>Lottery B</td><td>Expected value of Lottery A</td><td>Expected value of Lottery B</td></tr><tr><td>10% 100 PLN; 90% 80 PLN</td><td>10% 185 PLN; 90% 5 PLN</td><td>82</td><td>23</td></tr><tr><td>20% 100 PLN; 80% 80 PLN</td><td>20% 185 PLN; 80% 5 PLN</td><td>84</td><td>41</td></tr><tr><td>30% 100 PLN; 70% 80 PLN</td><td>30% 185 PLN; 70% 5 PLN</td><td>86</td><td>59</td></tr><tr><td>40% 100 PLN; 60% 80 PLN</td><td>40% 185 PLN; 60% 5 PLN</td><td>88</td><td>77</td></tr><tr><td>50% 100 PLN; 50% 80 PLN</td><td>50% 185 PLN; 50% 5 PLN</td><td>90</td><td>95</td></tr><tr><td>60% 100 PLN; 40% 80 PLN</td><td>60% 185 PLN; 40% 5 PLN</td><td>92</td><td>113</td></tr><tr><td>70% 100 PLN; 30% 80 PLN</td><td>70% 185 PLN; 30% 5 PLN</td><td>94</td><td>131</td></tr><tr><td>80% 100 PLN; 20% 80 PLN</td><td>80% 185 PLN; 20% 5 PLN</td><td>96</td><td>149</td></tr><tr><td>90% 100 PLN; 10% 80 PLN</td><td>90% 185 PLN; 10% 5 PLN</td><td>98</td><td>167</td></tr><tr><td>100% 100 PLN; 0% 80 PLN</td><td>100% 185 PLN; 0% 5 PLN</td><td>100</td><td>185</td></tr></table> |
Subsets and Splits
No community queries yet
The top public SQL queries from the community will appear here once available.